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ABSTRACT 
Cunently, asthma affects 25 .7 million people in the United States and is increasing in 
prevalence worldwide, with young children at high risk. Recent studies show that early 
environmental exposure can lead to asthma and impair lung function. While the 
development of asthma is not fully understood, findings indicate that cigarette smoke, 
ozone, allergen, or viral exposure to an immature lung can induce changes in airway 
innervation. However, the mechanisms underlying these changes and how these changes 
affect lung function are unknown. 
Normally, lung innervation plays a role in coughing, sensing, and breathing. We found 
that embryonic lung innervation requires brain-derived neurotrophin factor (BDNF) 
signaling and postnatal lung innervation requires neurotrophin 4 (NT4) signaling. Since 
both of these neurotrophins signal through tyrosine kinase receptor B (TrkB), they have 
temporally distinct roles in airway smooth muscle (ASM) innervation. We show that 
neurotrophins are released from ASM and act as target-derived signals for ASM 
Vll 
innervation. We also show that early allergen exposure in neonatal mice increase 
NT4/TrkB signaling leading to ASM hyper-innervation. Notably, genetic disruption and 
small molecule blockade ofNT4/TrkB signaling in early allergen exposed neonates 
prevented both acute and persistent aitway hyper-reactivity without affecting baseline 
airway function or inflammation. Fmthermore, biophysical assays using lung slices and 
isolated ASM cells demonstrated that NT4 was required for ASM hyper-contractility 
induced by early-life allergen exposure. 
Together, our fmdings show that the NT4/TrkB dependent increase in innervation plays a 
critical role in altering the ASM phenotype during postnatal growth, thereby linking 
early-life allergen exposure to persistent airway dysfunction. Our fmdings may explain 
why children who are exposed to environmental insults often develop asthma later in life. 
Findings from this study may also provide new pathways and targets for novel allergic 
asthma therapies. 
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CHAPTER 1: Mechanisms of respiratory innervation during embryonic 
development 
1.1 Summary 
Understanding the development of lung innervation is impmiant because innervation 
regulates lung functions such as coughing, breathing, mucus secretion and clearance, 
blood flow, and inflammation. A growing body of evidence now shows that impaired 
lung innervation can lead to improper lung development, COPD, and asthma. However, a 
solid understanding of the nmmal development of lung innervation will bolster these 
studies and perhaps provide new pathways to explore. The respiratory tract consists of the 
trachea and lungs, and is innervated by a combination of intrinsic neurons, whose cell 
bodies reside within the tissue, and extrinsic neurons, whose cell bodies are located in the 
central nervous system and nodose, jugular, and dorsal root ganglia. While lung 
innervation is not a new topic, new tools are breathing life into the field of lung 
innervation. Here, I discuss the signaling mechanisms that underlie innervation of the 
embryonic respiratory tract. 
1.2 Introduction 
The mammalian respiratory tract consists of the trachea and lung. It arises from ventral 
foregut endoderm ( 1 ). After progenitor specification, the lung primordia bifurcate 
ventral-laterally to form two primary lung buds. These buds continue to invade the 
surrounding mesenchyme, elongate, and branch to ultimately form a tree-like stmcture of 
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epithelium tubules and alveoli. Along with lung bud fmmation, the trachea forms 
ventrally and separates from the primitive esophagus that is formed in the dorsal side of 
the foregut. Meanwhile, the mesenchyme fmms from lateral plate mesode1m and gives 
rise to other cell types in the respiratory tract, such as airway smooth muscle (ASM), 
tracheal cartilage, lymphatics, and blood vessels (1). In mice, the trachea and lung form 
around E9, and the respiratory tract continues to develop after birth before reaching 
maturity around 3-4 weeks postnatally (1-3). 
During respiratory tree development, a complex neuronal network forms ( 4). This 
network includes axons from extrinsic neurons, whose cell bodies are located outside of 
the respiratory tract, and intrinsic neurons whose cell bodies reside in the trachea and 
major bronchi and cluster to form ganglia (Fig. 1) (5,6). Previous studies identified the 
location of extrinsic neuronal cell bodies by using a combination of 
retrograde/anterograde labeling techniques, immunohistochemistly, and microscopy (7-
12). Extrinsic neurons within the dorsal and ventral respiratory nuclei in the medulla 
oblongata and within the jugular and nodose ganglia supply parasympathetic efferents 
and most of the sensory afferents, respectively (Fig. lB) (6,13-15). These axons travel 
along the vagus nerve to innervate ASM and neuroendocrine bodies (NEBs) in the lung 
epithelium (Fig. lB) (13,16). Some efferents also connect to intrinsic neurons that 
provide post-ganglionic parasympathetic input to the trachea and bronchi (Fig. 1A) (6). In 
addition, sensory afferents from the dorsal root ganglia connect with thoracic ganglia to 
supply sympathetic innervation to the blood vessels and submucosal gland (Fig. 1) (6) . 
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This complex, neural network functions to control breathing, smooth muscle tone, and 
mucous secretion and to trigger reflexes such as cough (13-15). 
Although lung innervation has been described by previous studies in humans, primates, 
rodents, and several other animals, signals that regulate respiratmy neurogenesis are not 
fully understood (17-20). Here, we review current knowledge on mechanisms of 
respiratory neurogenesis during embtyonic development. Most studies on neurogenic 
signals were performed in mice, where ASM and NEBs are the major targets of 
innervation. This chapter is designed to highlight key findings in the development of 
respiratory tract innervation rather than a comprehensive overview of every study 
published in this field. We apologize to authors whose conuibution is not acknowledged. 
1.3 Intrinsic neurogenesis within the respiratory tract 
Earlier observations in the airways of humans and other species show that intrinsic 
neurons express neural crest cell markers, suggesting their neural crest migin (21,22) . 
Follow-up studies using engraftment of avian neural tissues and lineage labeling in 
mouse embryos definitively prove that intrinsic neurons in the respiratory tract are 
exclusively derived from vagal neural crest cells (23,24). These neural crest cells 
generate both neurons and glial cells that cluster to form ganglia, mostly found in the 
dorsal trachea and upper respiratory tract (Fig. lA) (23,24). As the size of the airway 
tapers off along the proximal-distal axis of the respiratory tree, there are fewer intrinsic 
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neurons (23,24). In mice, a small number of intrinsic neurons are located in the 
secondary and tertia1y bronchi with little to none in the distal lung (Fig. IA). 
In addition to intrinsic neurons in the respiratmy tract, vagal neural crest cells also give 
rise to enteric neurons in the gastrointestinal tract (25,26). These two groups of neural 
crest cells likely migrate together initially. Upon separation of the trachea from the 
esophagus at E1 0.5 in mouse emb1yos, neural crest cells that migrate into the space 
between the esophagus and the trachea begin to take different paths (23,24). 
Innervation of the gastrointestinal tract by enteric neural crest cells is well characterized 
compared to the respiratory innervation by intrinsic neurons. Expressed in the enteric 
wall, glial cell derived neurotrophic factor (GDNF) is an essential chemo-attractant for 
enteric neural crest cells (27-30). GDNF belongs to a family that also includes neurturin, 
artemin, and persephin. Each family member binds to unique GDNF family co-receptors 
1, 2, 3, and 4 (GFRal-4), respectively (31,32). When the GDNF family ligand binds to 
the GFRa co-receptor, the common tyrosine kinase receptor RET is recruited for 
downstream signaling (31 ,32). Enteric neural crest cells predominantly express GFRa 1 
(24,30). Consistently, genetic disruption ofGDNF or RET diminishes the migration of 
enteric neural crest cells and subsequent formation of the enteric nervous system (27-
30,33). 
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Figure 1-1. Schematic diagram showing extrinsic nerves and intrinsic innervation of the respiratory tract. Extrinsic neurons have their cell 
bodies in the jugular, nodose, and petrosal ganglia within the brainstem. These extrinsic neurons extend their axons via the vagus nerve (in red and 
blue) and provide parasympathetic respiratory i1mervation. In addition, sensory neurons located in the dorsal root ganglion also provide extrinsic 
innervation (in green) to the respiratory tract. (A) Neural crest-derived intrinsic neurons (in blue) cluster within the trachea and main bronchi. Intrinsic 
neurons express Ret receptor. The survival, proliferation and/or differentiation of intrinsic neurons within the respiratmy tract is dependent on the 
GDNF family ligands that include GDNF and neurturin. (B) ASM in the embryonic lung expresses BDNF. BDNF serves as a target-derived 
neurotrophic signal for extrinsic innervation by TrkB+ extrinsic nerves. The lung is largely devoid of intrinsic neurons. 
In contrast, GDNF is not expressed in the trachea, and GDNF deficiency has no effect on 
the respiratmy intrinsic neurons (23,24). This suggests that respiratory neural crest cells 
depend on different chemo-attractants for migration. Further characterization of other 
GDNF family member and receptor expression shows that neurturin is expressed in the 
respiratmy tract, and that respiratmy neural crest cells express both GFRal and GFRa2 
(24). However, the neurturin knockout mouse emb1yos have normal airway intrinsic 
innervation (24 ). In addition, loss of RET function, which demolishes the signaling 
activity of all GDNF family members, does not affect the number of respiratmy intrinsic 
neurons at E14.5 (23). These findings indicate that the respiratory neural crest cells are 
independent of the GDNF family for migration into the respiratmy tract. However, Ret 
deficiency leads to a 50% reduction in the size of the ganglia at E18.5 (24). Thus, GDNF 
family signaling, through the Ret receptor, likely plays a role in the survival, 
proliferation, and/or differentiation of these neural crest cells after they reach the 
respiratmy tract. Signals for the migration of neural crest cells in the respiratmy tract 
have yet to be identified. 
In addition to the difference in essential migratmy signals between the respiratory and 
gastrointestinal neural crest cells, cells that migrate into these two organs also differ in 
their progenitor status. Recently, using avian embryos, the Bums lab has shown that after 
graft into the vagal neural tube, neural crest cells that have already reached the gut can 
still migrate into the lung and the gut (34). However, neural crest cells collected from the 
lung fail to migrate after graft (34 ). These findings suggest that respiratory neural crest 
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cells are committed once they reach their destination whereas gastrointestinal neural crest 
cells maintain their migratory potentials even after they migrate into the gut. 
1.4 ASM innervation by extrinsic neurons 
While intrinsic neurons likely provide parasympathetic innervation to the trachea and 
main bronchi, a large body of evidence indicates that intrinsic neurons do not contlibute 
significantly to lung innervation (Fig. 1B). Firstly, most of inti·insic neurons are located 
in the trachea and main bronchi (19,23,24). Only a small number of intrinsic neurons are 
found in the secondary and tertiary bronchi with little to none in the distal lung (23,24). 
Secondly, inti·insic neurons have short axons, suggesting that they function locally (35). 
Thirdly, although RET mutant embryos have a reduction in the size of resident ganglia at 
E18.5, they have no defects in lung innervation (24). Finally, vagotomy results in an 
almost complete loss of innervation of airway targets, such as NEBs (36). Collectively, 
these findings indicate that the lung is innervated predominantly by extrinsic neurons. 
However, the role of intrinsic lung innervation cannot be fully elucidated until functional 
data is obtained from animal models selectively deficient in intrinsic neurons. 
During embryogenesis, the outgrowth of axons into the distal lung is closely associated 
with the formation of ASM. Studies in the fetal porcine and human lung show that the 
developing tubules are covered in a layer of ASM and ensheathed in a newly formed 
neuronal network (18,19,37). Two large nerve trunks run the length ofthe bronchial tree. 
They give rise to a network of bundles, with fine fibers covering up to the growing tips of 
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the airways ( 18, 19). This close temporal and spatial relationship between ASM formation 
and axon outgrowth suggest an ASM-derived trophic mechanism for innervation. 
The extrinsic neurons depend on the nerve growth factor (NGF) family for ASM 
innervation. The NGF family includes NGF, brain-derived neurotrophic factor (BDNF), 
neurotrophin 3 (NT3), and NT4 (38,39). They signal through high-affinity tyrosine kinase 
Trk receptors with relative selectivity: TrkA for NGF, TrkB for BDNF and NT4, and 
TrkC for NT3. Both BDNF and NT4 are expressed by embryonic ASM (40). The BDNF 
knockout embryos have reduced axon branches and shortened axons targeting the ASM 
without any change in lung morphogenesis or ASM differentiation ( 40). Thus, BDNF 
serves as a target-derived neurotrophic factor for ASM innervation by extrinsic neurons 
during embryogenesis ( 40). These findings also provide further evidence that intrinsic 
neurons and extrinsic neurons require distinct neurogenic signals for innervation of the 
respiratory tract. 
To ensure appropriate innervation, BDNF expression needs to be temporally coordinated 
with ASM differentiation. Notably, BDNF mRNA is expressed as early as E11.5 in the 
lung mesenchyme prior to its differentiation into ASM (40). To coordinate, a post-
transcriptional regulation is at play to repress the translation of BDNF mRNA until ASM 
is formed. One of the mechanisms of post-transcriptional regulation ofBDNF expression 
is through a microRNA, miR-206. miR-206 is expressed in lung mesenchyme, and its 
expression is down-regulated upon ASM differentiation. In addition, miR-206 targets 
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BDNFrnRNA for degradation (40). Fmihermore, the miR-206 knockout mice exhibit 
premature airway innervation (40). Collectively, these findings suppmi miR-206 as a 
post-transcriptional regulator for coordinated BDNF protein expression, ASM 
differentiation, and ASM innervation. 
Additionally, NT4, which binds to the same TrkB receptor as BDNF, may play a 
redundant role in ASM innervation. Consistent with this hypothesis, previous studies 
showed that mice deficient in both BDNF and NT4 have a diminished number of neurons 
in the nodose-petrosal ganglion complex, one of the locations where extrinsic neurons 
reside (Fig. 1) ( 41 ). In addition, airway innervation was more reduced in the TrkB_1_ mice 
than in the NT4_1_ mice ( 42). 
1.5 NEB innervation 
NEBs are specialized clusters of pulmonary neuroendocrine cells that originate from the 
airway epithelium in the mammalian lung. Whereas solitary pulmonary neuroendocrine 
cells are found in the trachea, bronchioles, and terminal airways, NEBs are localized only 
in the intrapulmonary airways (43). The cytoplasm of the NEB contains secretory 
granules that are loaded with bioactive molecules, such as neuropeptide, monoamines and 
purine transmitters (16,36,43). NEBs are usually found at or near the bifurcation sites of 
the airway (36) and juxtapose invariant Clara cells, a cell population with stem-celllike 
properties ( 44,45). Due to these unique structural, chemical, and positional properties, 
NEBs have been speculated to function as mechanoreceptors and play a role in oxygen 
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sensing and regeneration of the distal pulmonary epithelium (43 ,46,47). However, precise 
roles ofNEBs remain elusive. 
NEBs in the lung epithelium are innervated by a mixture of sensory and cholinergic 
nerves (36). These sensory afferents originate from the nodose ganglia and dorsal root 
ganglia, and the cholinergic efferents come from the brain stem and intrinsic ganglia 
(16,36). NEB innervation by P2X2 + and P2X3 + axons is reduced in NT4_1_ mice, indicating 
that NT4 is required for NEB purinergic innervation (48). Whether NEB innervation 
regulates the role ofNEBs dming homeostasis and regeneration of the lung epithelium is 
unknown. 
1.6 Conclusion 
Despite recent progress on the mechanisms of respiratory innervation, future studies are 
required to fully understand these processes. For example, additional signals that control 
NEB innervation remain to be identified. In addition, mechanisms underlying ASM 
innervation in postnatal life need to be further investigated. Lately, mounting evidence 
indicates that altered innervation is involved in the pathogenesis of respirat01y diseases 
( 49-51 ). Identification of the signals required for disease-related neural plasticity will 
likely provide groundwork for identification of new therapeutic targets. 
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CHAPTER 2: Development of Childhood Asthma and Persistence into Adulthood 
2.1 Summary 
Asthma requires both genetic predisposition as well as appropriate allergen exposure for 
development. It is becoming clear that exposure to various environmental factors in early 
childhood can affect, either negatively or positively, the developmental process of 
asthma. While the pathways leading to asthma are not fully understood, recent fmdings 
indicate that environmental factors such as chemical initants, allergen, or viral exposure 
in an immature lung induce hyper-innervation of airway smooth muscle cells . Increased 
innervation can occur through direct neuronal stimulation by chemical irritants such as 
ozone and cigarette smoke, or by cytokine stimulation following immune cell activation 
initiated by allergen exposure. In all cases, neurotrophins are critical for this effect. 
Recent findings have begun to identify the mast cell as a critical immune component 
triggered by allergen exposure and the cellular bridge between allergen stimulation and 
hyper-innervation. Animal models also indicate that hyper-innervation results in 
increased airway resistance that persists well into adulthood, even in the absence of 
continued allergen exposure. These findings suggest that structural changes that occur in 
the developing lung following chemical or allergen insult have a sustained impact on 
adult lung function, thereby contributing to a hyper-reactive lung associated with 
asthmatic bronchoconstriction. This chapter highlights recent fmdings regarding lung 
development and neuronal alterations that occur with chemical or antigenic exposure. 
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2.2 Introduction 
The incidence of asthma has been increasing worldwide for the past decade; however, it 
is unclear why. A strong connection has been established between viral infection early in 
life with subsequent alteration in airway epithelial cells, development of Th2-mediated 
inflammation, and allergen-induced bronchoconstriction (52-57). Longitudinal studies 
have indicated that viral infections (rhinovirus and RSV) in infants lead to development 
of wheeze and that these children have a higher likelihood of becoming asthmatic later in 
life (58-61). A complex association therefore exists between genetic predisposition, viral 
exposure, allergen exposure, alterations in immune responses, and onset of asthma. While 
the lung is still developing post birth, early allergen exposure may alter lung function. As 
discrete steps in lung development in humans cannot be captured for practical reasons, 
many insights on postnatal lung development have been gained from studies in mice and 
non-human primates. The mouse lung matures, based on alveolarization, in early 
adulthood, by day 36 (63 ,64), while the non-human primate lung shows rapid growth 
through age 2 with slower growth until 7 years of age (65). The human lung shows rapid 
growth through age 3 with slower growth until age 8 (3,66), but is not considered fully 
mature until early adulthood. 
Independent of the cause or age of onset, the definitive clinical feature and primary 
pathologic component of patients with asthma is reversible hyper-reactivity of the airway 
smooth muscle (ASM). While inflamed lung tissue and mucus secretion are contributing 
factors, bronchoconstriction represents the major cause for wheeze and shortness of 
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breath. Under normal physiological conditions, acetylcholine released from innervating 
cholinergic nerves is the most potent signal to trigger bronchoconstriction. While signals 
:from immune cells likely contribute to deregulated ASM contraction in asthma, neuronal 
hyper-reactivity is critical for antigen-mediated bronchoconstriction (67). Therefore, 
understanding the effects of early exposure to allergens and viruses on the developmental 
process of nerve growth in genetically predisposed individuals is critical to understanding 
asthma pathogenesis. Data now indicate that allergen exposure during early childhood 
result in permanent structural changes to the lung, pa1iicularly in ASM innervation 
(68,69). Identification of pathways triggered by these exposures could lead to novel 
modalities for therapeutic approaches that prevent or delay asthma development later in 
life. 
Much of the data in humans on interactions between the neural and ASM axis are from 
allergen challenge studies. In this regard, there is a significant body of literature that 
illustrates the relationship between the production of neurotrophins (NTs) in the lung 
following allergen exposure and subsequent development of asthmatic responses in adults 
(70). Several studies have shown an increase in the levels ofNTs, such as nerve growth 
factor (NGF) in the bronchial lavage fluid (71) and blood serum (72,73) of adult 
asthmatic patients and mice (74,75). Infiltrating immune cells, ASM, and lung epithelium 
produce elevated levels ofNTs. The presence ofNTs affects many different cell types as 
it not only alters the neurochemical properties of innervating axons in the airway, but also 
affects the function of resident and recruited immune cells (76-84). In addition to the 
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crosstalk between immune cells and nerves through NTs, axons also release a vatiety of 
neuropeptides in response to mechanical stimuli and allergen insults that are required for 
induction of the inflammatory response. In suppoti of a direct communication between 
nerves and immune cells, the sensoty neuronal ion channel expressed in the airway 
chemosensory nerves, TRP Al, was shown to be essential for development of allergic 
airway inflammation and hyper-reactivity in adult mice (85). The genetic deletion of 
TRP A 1 or antagonistic mediators of TRP AI activation demonstrated the inhibition of 
allergen-induced leukocyte recruitment, reduced Th2 cytokines, and reduced mucin 
production along with a significant reduction in airway reactivity to contractile stimuli 
(85). This data suggests that TRP Al is an integral link between the nervous system and 
the immune system during asthmatic responses. Mast cells also appear to facilitate 
interactions with the nervous system as they have been shown to release chemicals that 
directly activate both the neurons and ASM (86-95). 
As early allergen or viral exposure appears pivotal for subsequent development of the 
asthmatic response, the relationship between the immune and nervous systems becomes 
more complex. This increased complexity is centered on the maturing state of both 
systems when exposure initially occurs. We, and others, have recently identified 
significant differences in cytokine production and T regulatory cell function in peripheral 
immune cells obtained from children at birth through three years of age (96-1 02) as 
compared with adult cellular responses. The differences in cytokine production along 
with the observed blunted T regulatory cell responses suggest that regulation of the 
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immune system has not fully developed. Similarly, studies indicate that the nervous 
system in the lung does not fully mature until close to adulthood (see below). These 
findings suggest that the interactions between these two systems following allergen or 
viral pe1turbation would be markedly different in children as compared with adults. 
Along these lines, our focus has been on the association between innervation and 
asthmatic responses in the developing lung. We have identified a strong connection 
between NT production and the subsequent increase in innetvation in the setting of 
allergic sensitization and challenge. However, to fully understand the effects of allergen 
exposure on innervation, we first need to gain a better understanding of axon-genesis in 
the airway during embryogenesis and postnatal growth. Changes resulting from early 
exposure to allergen or viral exposure can then be addressed along with their underlying 
mechanisms. Based on previous studies, we propose that altered NT expression from 
early allergen exposure has a profound and long-term impact on airway structure and 
function. These changes would be relevant to contribute to asthma pathogenesis in the 
neonatal and early infant periods. 
2.3 Lung development and innervation 
The timeframe and processes for lung development in the mouse have been extensively 
investigated. Mouse lung development is similar to human lung development except the 
mice have different numbers of airway branches proximal to the terminal bronchiole and 
lack submucosal bronchial glands. Therefore, the mouse can be used as a model of lung 
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development. The mouse is also used as a common model to investigate pathogenic 
pathways for asthma development; thereby creating a model that can mimic asthma 
development in humans (103). In the mouse, the lung begins to develop at embryonic day 
9.5 (E9.5) with bi1ih occurring at E21 (1). Innervation of the embryonic lung begins to 
develop at El2 following lung branching, which begins at Ell (19,104,105). The newly 
generated axons extend into the distal lung and are found adjacent to the developing 
ASM. They continue to grow and form a complex, neural network primmily innervating 
the ASM with some innervation of airway epithelium. Throughout the maturation 
process, innervation continues to grow and develop postnatally as the axons extend and 
branch along with maturation of their neurochemical properties and synapses ( 18). 
Sparrow et al. report that the distal airways of infants who died of Sudden Infant Death 
Syndrome had increased ASM innervation and an abundant neural plexus ensheath the 
airways. It is thought that these axons play a role in the cough reflex through neural 
control of bronchoconstriction. In the mouse, we have determined that the postnatal 
innervation process appears most active around postnatal day 14 (Pl4) with little 
detectable increase after P21. 
The mammalian respiratory tract consists of the trachea and lungs and is innervated by a 
combination of intrinsic neurons, whose cell bodies reside within the lung, and extrinsic 
neurons, whose cell bodies are located in the central nervous system and nodose, jugular, 
and dorsal root ganglia (19,20,106). During axongenesis, neurogenic factors, including 
the glial cell-derived neurotrophic factor (GDNF) family and the nerve growth factor 
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(NGF) family, are required for the survival, development, and differentiation of 
peripheral afferent and efferent neurons (38,39,107,108). Studies on embryonic lung 
neurogenesis demonstrate that intrinsic neurons respond to the GDNF family including 
GDNF, neuturin, artemin, and persephin (104). The smooth muscle in the trachea and 
major bronchi express both GDNF and neuturin that likely function redundantly to 
support the development of intrinsic neurons. These intrinsic neurons form ganglia along 
the trachea and main bronchi and extend short axons to innervate nearby ASM (35). 
In contrast, the extrinsic neurons respond to the NGF family that includes NGF, brain-
derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4) (40). 
NGF, NT3, and BDNF have all been shown to be present in human lung tissue (109). The 
NTs are expressed by ASM to serve as target-derived chemoattractants, guiding the 
axons to form a neuromuscular junction with the ASM ( 40). These extrinsic neurons 
provide parasympathetic innervation to induce bronchoconstriction in the lung. In 
addition, the sensory afferents and sympathetic nerves from extrinsic neurons also 
regulate ASM contractility ( 1 06). 
Our previous work has shown that BDNF is required for embryonic ASM lung 
innervation. The BDNF knockout mouse is embryonic lethal, but early embryonic studies 
have shown that there is a loss of fine axons in the lung as well as an overall shortening 
of axons targeting the ASM ( 40). The BDNF protein expressed in the lung mesenchyme 
(precursor cells that develop into ASM) at El3.5 is temporally associated with axon 
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outgrowth also seen at day E13.5. At birth, BDNF protein levels decline as NT4levels 
increase postnatally. The protein levels ofNT4 also conespond to the plateau in 
innervation at P14 suggesting that NT4 may be an impmtant postnatal NT and that 
changes in innervation associated with allergen or viral exposure likely result following 
changes in NT expression. Both BDNF and NT4 signal through the transmembrane NT 
receptor, tyrosine kinase B (TrkB), implying that TrkB also plays a key role in 
innervation development of the lung. The TrkB systemic knockout mouse is perinatally 
lethal, but has been shown to have a decrease of lung innervation in both airway and 
vascular smooth muscle ( 42). 
Muscarinic receptors are acetylcholine receptors that potentiate neurotransmitter 
signaling. There are five muscarinic receptor subtypes, which belong to the family of 
seven transmembrane G-protein coupled receptors. Two of these have been associated 
with airway constriction in asthma models, M2 and M3 (111). Predominately, M3 
receptors are found on the ASM, while M2 receptors are found on parasympathetic 
nerves in the lung. The M2 receptors serve as a negative feedback mechanism to inhibit 
fmther acetylcholine release from the synapses. M2 is also expressed by the ASM but 
signals less dominant to M3. Murine studies have identified a down-regulatory response 
of M2 expression on ASM following house dust mite allergen challenge. Genetic and 
protein analysis demonstrated that the M3 gene and protein were significantly down-
regulated in C57B6 mice, as compared with Balb/c mice (112). This is consistent with the 
finding that bronchoconstriction is greater in Balb/c mice. Conversely, the use ofM3 
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antagonists in allergic asthma models has demonstrated inhibition of airway constriction 
(113). 
2.4 Effects on innervation with early allergen exposure 
Allergen exposure in a lung that is still undergoing developmental changes has a higher 
likelihood of effecting petmanent changes compared to allergen exposure in a mature 
lung. The development of peripheral sensory neurons is dependent on the appropriate 
timing and quantity ofNT secretion. This creates a critical developmental window for 
infants where disruption of the normal NT secretion process could lead to irreversible 
changes in lung innervation, which is associated with greater risk of asthma development. 
Allergen exposure within this window increases production ofNTs leading to an increase 
in lung innervation. The highly innervated airways are more prone to constriction. Data 
from several different models of asthma have indicated that early exposure to allergen, 
ozone, or tobacco smoke alters innervation that is highly correlated with development of 
asthmatic responses, ·detected even in older animals. In particular, Plopper et al. report 
that exposure of rhesus monkeys, in the first several months of life, to ozone and/or house 
dust mite allergen (HDMA) produced extensive airway remodeling including reduction in 
the number of airways, hyperplasia of the bronchial epithelium, increase in mucous cell 
number, changes in ASM abundance and orientation, basement membrane thickening, 
and reorganization of the airway vascular and immune system (114-118). Kajekar et al. 
demonstrate that, in infant macaques, repeated exposures ofHDMA and/or ozone 
exposure from 1 to 5 months of age caused an initial decrease in nerves innervating the 
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epithelium in the midlevel intrapulmonary aitways (69). When the animals were allowed 
to recover for 6 months in the absence of further ozone or HDMA exposure they 
observed persistent hyperinnervation of the pulmonary epithelium (69). This suggests 
that early loss of innervation following allergen exposure, in the primate, leads to an 
adaptive process resulting in restoration of innervation beyond pre-challenge levels. The 
mechanism for the initial decrease in innervation has not been identified; however, 
subsequent hyperinnervation is detected within one year of life and persists into 
adulthood. The hyperinnervation is likely associated with persistent proliferative 
mechanisms, such as NTs, that are delayed in generation. Our studies demonstrate some 
similarities with these findings. We use neonatal WT mice, which are exposed to 
ovalbumin (OVA) on days 5, 10, and 18-20 or cockroach extract on days 5, 10 and 15 
post-birth. We have determined that at day P21 there is increased ASM innervation and 
that these mice exhibit increased baseline airway resistance, demonstrating a similar 
persistence in hyperinnervation to that in ptimates. 
Based on studies that identify essential neurogenic signals for lung innervation, it is 
likely that altered NT expression in developing neonatal lungs may lead to changes in 
ASM innervation and long-te1m influence on ASM function. Consistent with this notion, 
NGF and BDNF have both been shown to be increased in the bronchoalveo1ar lavage 
fluid of infants with RSV infection (119). Neonatal rats exposed to ozone had an increase 
in substance P (sub. P) containing nerve fibers (4,120). Infant monkeys exposed to ozone, 
house dust mite antigen, or both all had reduced lung innervation and function however 
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repeated exposures led to de novo development of Protein gene product 9.5 positive cells 
(121 ). In our model of OVA-induced allergic asthma in neonatal mice, there was an 
increase in ASM innervation. NT4 protein expression was also increased with OVA 
treatment, suggesting that allergen exposure increases NT4 production to increase lung 
innervation. The effects of allergen exposure on increasing innervation, however, are 
limited to the early postnatal period. When adult mice are challenged with OVA allergen 
at eight weeks there is no detectable change in levels of innervation, despite increases in 
NT production. A similar situation exists in the primate and mouse where early postnatal 
exposure to tobacco leads to long-term increases in lung innervation, while late postnatal 
tobacco exposure does not elicit changes in innervation (69,122). The increase in NTs 
without increased evidence of innervation in the adults indicates that the developmental 
window is regulated by neuronal responses and not by restricted production of NT 
factors. These data also highlight the notion that susceptibility to hyper-innervation 
appears to be particularly prevalent in the developing lung. 
2.5 Asthma persistence into adulthood 
Asthma is a chronic disease that appears to result from a number of coexisting conditions. 
Given genetic predisposition, the process is initiated early in life with allergen exposure. 
Based on animal studies, low level exposures for extended periods of time are required to 
trigger both neurological and inflammatory responses. The neuronal response is 
characterized by an increase in innervation, which in a number of animal models, persists 
into adulthood. Our studies demonstrate that increased innervation is associated with a 
baseline increase in airway resistance in the neonatal mouse, which persists well into 
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adulthood. This is consistent with a number of birth-cohort studies demonstrating that 
over 70% of young adults with asthma had episodes of wheeze by age six. Childhood 
rhinovirus and RSV infections are also strongly associated with development of wheeze 
early in life and with development of asthma later in life. Recent studies report that 
children with high risk factors for asthma with confumed rhinovirus infections before age 
3 are 10 times more likely to develop asthma later in life (123-125) and reviewed in (56). 
These studies also demonstrate that children with confitmed cases ofRSV infection are 
four times more likely to develop asthma by age 6. This association between RSV 
infection and wheeze decreases beyond age 6 and is reported to be absent in children 13 
years and older. Allergen presence, such as cockroach antigen or HDMA, is typically 
ubiquitous in urban settings where asthma prevalence is higher. Therefore, it is difficult 
to separate viral contributions from allergen contributions to changes in innervation. It is 
conceivable that rhinovirus or RSV infection of the epithelium in the upper and lower 
respiratory tract leads to changes that affect innervation. The airway epithelium is a 
cellular source for NTs in the lung, and their production is induced during viral infections 
(126,127). It is clear that pathologic and permanent changes in the lung that are initiated 
by early life allergen and/or viral exposure. These changes appear, in particular, to affect 
the process of ASM innervation. Our mouse studies indicate that allergen exposure in the 
early postnatal period results in persistent hyper-innervation and increased baseline 
airway resistance but without airway inflammation; and that these changes are still 
present at three months of age. The maintained increase in baseline airway resistance 
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indicates a potential contributory factor to the persistence in asthmatic responses in 
adults. 
2.6 Conclusion 
Data from animal and clinical studies have indicated a strong correlation between early 
allergen or virus exposure and predisposition towards the development of asthma later in 
life. While a complete understanding of this mechanism is still lacking, it is becoming 
clear that pe1manent physiological changes occur following exposure that render a 
genetically predetermined individual more susceptible to develop asthmatic symptoms. 
The most notable change is an increase in airway innervation; coincident with elevated 
levels ofNT production, in particular NT4. Animal studies also indicate that there is a 
critical but definitive time frame where allergen or viral exposure affects innervation 
development, which appears to coincide closely with lung maturation. This concept 
provides an opportunity for therapeutic application of innervation inhibitors, which if 
given during that critical time period in development could reduce and/or delay the onset 
of asthma in older children. Even if treatments are not effective at preventing asthma 
development, delaying the onset of asthma by ten years may reduce the risk of relapse by 
approximately 70% (128). Additional studies are required to more fully elucidate the 
association of increased innervation with onset and persistence of asthma, and to better 
understand the cellular mechanisms involved in this process. 
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CHAPTER 3: A Shh/miR-206/BDNF cascade coordinates innervation and 
formation of airway smooth muscle 
3.1 Summary 
Dysfunctional neural control of ai1way smooth muscle (ASM) is involved in 
inflarnrnatmy diseases, such as asthma. However, neurogenesis in the lung is poorly 
understood. This study investigates developmental mechanisms of ASM innervation, a 
process that is highly coordinated with ASM formation during lung branching 
morphogenesis. We show that brain-derived neurotrophic factor (BDNF) is an essential 
ASM-derived signal for innervation. Although BDNF rnRNA expression is temporally 
dissociated with ASM formation and innervation, BDNF protein is coordinately produced 
through post-transcriptional suppression by miR-206. Using a combination of chemical 
and genetic approaches to modulate sonic hedgehog (Shh) signaling, a pathway essential 
for lung branching and ASM formation, we show that Shh signaling blocks miR-206 
expression, which in tum increases BDNF protein expression. Together, our work 
uncovers a functional cascade that involves Shh, miR-206 and BDNF to coordinate ASM 
formation and innervation. 
3.2 Introduction 
The respiratory tract, which consists of the trachea, bronchi and lung, is innervated by 
two types of neurons that are distinguished by the location of their cell bodies. Intrinsic 
neurons have cell bodies clustered along the smooth muscle stripe in the trachea and 
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major bronchi (19,24,129-131). These neurons have short axons that innervate nearby 
targets (35). In contrast, cell bodies of extrinsic neurons are located in jugular/nodose 
ganglia, dorsal root ganglia, and sympathetic ganglia, while their axons extend into the 
lung to innervate ASM and neuroendocrine cells (13,132). 
Neural innervation of the respiratory tract plays a key role in physiological reflexes, such 
as coughing, and regulates smooth muscle tone (13,133). In addition, neural inputs to 
neuroendocrine cells may be involved in regeneration of airway epithelium after injury 
(134). Furthermore, changes in innervation are associated with the development of 
airway diseases (75,135,136). 
Our previous studies demonstrate that the glial cell line-derived neurotrophic factor 
(GDNF) family is essential for intrinsic neurogenesis (24). Intrinsic neurons not only 
respond to members of the GDNF family in culture, they also require GDNF family for 
survival, as the number of intrinsic neurons is diminished by genetic disruption of GDNF 
family signaling (24,137). In contrast, ASM innervation in the distal lung remains 
unaffected in GDNF family mutants, indicating that the lung is primarily innervated by 
extrinsic neurons that require a different neurogenic signal. Sonic hedgehog (Shh) 
signaling is required at the tip of lung bud for branching and in the stalk to induce 
mesenchyme specification into ASM (1,138). 
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Shh is expressed in the lung epithelium and signals to the neighboring mesenchyme by 
binding to its receptor Patched. Upon binding, Shh triggers a cascade of signaling events 
that involves activation of Smoothened, transcription factor Glis, and expression of target 
genes, such as Gli1 and Patched-1. 
Around E12.5, which is before the appearance of the early smooth muscle marker, ex-
smooth muscle actin (cxSMA), in the lung buds, axons are primarily located within the 
major bronchi but do not extend into the lung (19,24). At El3 .5, axons extend into the 
distal lung and are found in approximation with developing ASM. Axons continue to 
grow and elaborate into a complex neural network during later embryonic stages (19). 
The temporal and spatial coupling between axon outgrowth and ASM formation suggest 
that an ASM-derived neurotrophic factor coordinates these two processes. 
Here, we investigate molecular mechanisms that coordinate ASM innervation and 
formation. We identified brain-derived neurotrophic factor (BDNF) as an essential ASM-
derived trophic factor for innervation and uncover a functional interaction between Shh 
signaling and BDNF expression via miR-206. 
3.3 Materials and Methods 
3.3.1 Mice 
Dermo1-Cre line (stock number: 008712), Rosa(SmoM2) line that carries the constitutive 
active SmoM2 allele in the ROSA26locus (stock number: 004339), BDNF1-line (stock 
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number: 002266) and Ptcl;Laczt line (stock number: 003081) were purchased from The 
Jackson Laboratories. The aSMA-HrGFP transgenic line in which a green fluorescent 
protein (hrGFP) is expressed under control of the rat aSMA promoter was generated at 
Boston University School of Medicine (139). The miR-206"1-line was kindly provided by 
Dr. Eric Olson at University of Texas Southwestem Medical Center (140). For timed 
pregnancy, mice were mated ovemight and the rooming of finding the vaginal plug was 
considered as embryonic day 0.5 (E0.5). All animal studies were approved by the 
Institutional Animal Care and Use Committee at Boston University Medical Campus. 
3.3.2 Histology and immunohistochemistry 
The lungs were fixed in 4% paraformaldehyde/PBS at 40°C overnight. After 
cryoprotection in 30% sucrose/PBS, 10 !J.m sections were collected. Sections were 
blocked for 1 hour in antibody dilution buffer (3% BSA, 10% goat serum, 2% horse 
serum and 0.1% Triton X -100 in PBS) and primary antibody applied for 2 hr at room 
temperature or ovemight at 4°C. Antibodies against NGF family members were 
purchased from Santa Cruz Biotechnology, including rabbit anti- NGF (1:100, sc-548), 
BDNF (1:100, sc-546), NT3 (1:50, sc-547) and NT4 (1:50, sc-545). Other primary 
antibodies include biotinylated TuJI antibody against neuron-specific class III -~ tubulin 
(1:200, BAM1195, R&D Systems) and mouse anti-aSMA (1:500, MS-113, Thermo 
Scientific). Antigen-antibody complexes were detected either by fluorescence or by 
chromogenic substrates. Fluorescently labeled whole lungs were imaged using a Zeiss 
Axiovert 1OOM LSM 510 equipped with an Argon and 2 ReNe lasers (Thomwood, NY). 
Compressed, tiled, Z-stack confocal images were presented and quantified. X -gal staining 
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to detect ~-galactosidase expression in Pte] ;LacZ: emb1yos was performed as described 
previously (24). 
3.3.3 Lung organ culture 
Lungs were dissected from E11.5 mouse embryos and maintained at air-medium interface 
on transwell inserts (Langsdorf et al., 2011 ). Embryonic lung organ cultures were treated 
with cyclopamine (0.5 J.!M, Calbiochem, Cat#239804) and SAG (1 J.lg/ml, Calbiochem, 
Cat#566660) for 48 hr before protein and gene expression analysis. 
3.3.4 Quantitative RT-PCR (qPCR) 
Total RNA was extracted from emb1yonic lungs using Trizol (Invitrogen). For mRNA, 1 
J.lg total RNA was reverse-transcribed using the Superscript III First-strand Synthesis 
System (Invitrogen) followed by quantitative PCR using Taqman Gene Expression 
Assays (Applied Biosystems). The relative level ofmRNA expression of the genes of 
interest was calculated by normalizing to 18s rRNA using b. Ct. For miRNA, 10 ng total 
RNA was subjected to reverse transcription using the Taqman MicroRNA Reverse 
Transcription Kit (Applied Biosystems) followed by qPCR. The relative level ofmiRNA 
expression was calculated by normalizing to U6 using b.Ct. 
3.3.5 Constructs and luciferase assay 
The 1.5 kb BDNF 3 'UTR was cloned by qPCR and then inserted downstream of firefly 
luciferase gene in psiCHECK-2 vector (Promega) using Xhoi/Notl cuts. miR-206 and a 
mutant rniR-206 with a deleted seed sequence (miR-206 mut) were cloned into a 
lentiviral vector pLVTHM using Spel restriction enzyme cut site. 293T cells were 
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transfected with the psiCHECK-2_BDNF 3'UTR and miR-206 using Fugene 6 
transfection reagent (Roche) and luciferase activity was measured by dualluciferase 
assay following manufacturer's protocol (Promega). 
miR-206 was cloned by PCR using following primers: 
forward primer: 5'GGACTAGTGGTCCTTGATCTCAGACTGAA 3' 
reverse primer: 5' GGACTAGTAGCCATATGAGCAGAGGAA 3' 
3.3.6 miRNAarray 
Aff)rmetrix GeneChip miRNA Array was used for miRNA profiling in control and 
cyclopamine treated lung organ cultures. Experiments were performed in triplicate, and a 
two-sample t-test was performed to identifY up-regulated miRNA expression in 
cyclopamine treated cultures. 
3.3. 7 In situ hybridization 
BDNF mRNA and miR-206 in situ hybridization was performed on 15 J.lm frozen 
sections using digoxigenin-labeled antisense RNA probe and LNA probe (Exiqon), 
respectively. The detailed protocol was described previously (141,142). To generate 
antisense probe for BDNF, a 126 bp DNA fragment was cloned into pGEM-T vector 
(Promega) after qPCR using following primers: 
BDNF-F: 5' CCACTGCCGGGGATCCGAGA 3'; 
BDNF-R: 5' TTTCATGGGCGCCGCCTTCA. 
3.3.8 Western blot analysis 
Embryonic lungs were homogenized in RIP A buffer containing proteinase inhibitor 
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(Roche Diagnostics) using PowerGen 125 (Fisher Scientific, Pittsburg, P A). Celllysates 
were collected and mixed with equal volume of 2X Laemmli Buffer. Proteins in the cell 
lysate (20 Jlg) were separated by NuPAGE® Bis-Tris gels (12%, Invitrogen) before 
transferring onto Hybond-ECL nitrocellulose membrane (Amersham Biosciences). 
Membranes were blocked with 5% BSA for an hour and incubated with primary 
antibodies (rabbit anti-BDNF (1 :500, H-117, sc-20981), rabbit anti-GAPDH (I: 100,000, 
Ab8245, Abeam)) in 2.5% BSA overnight at 4°C. After washing, the membrane was 
incubated in the secondary antibody followed by detection with ECL reagents. 
3.3.9 Statistical analysis 
The Student's t test was used for all analyses. Data were presented as the average and 
standard e1ror of a minimum of 3 independent experiments. 
3.4 Results 
3. 4.1 BDNF is required for ASM innervation. 
The nerve growth factor (NGF) family plays essential roles in neural innervation of target 
tissues (38,143). To identify neurotrophic factors that are required for ASM innervation, 
we characterized the expression of the NGF family in the embryonic lung. We found that 
BDNF was expressed selectively by ASM and vascular smooth muscle cells at El4.5, 
while NGF and neurotrophin 3 (NT3) were not detected (Fig. 3.1 A). Neurotrophin 4 
(NT4), which binds to the same high affinity TrkB receptor as BDNF, is also expressed 
by ASM but is restricted to proximal airways (Fig. 3.1 A). The expression ofBDNF and 
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NT4 in the ASM persists into later stages (Fig. 3.1 A). 
To investigate the role ofBDNF in ASM innervation, we compared neurogenesis in wild 
type and BDNF1- lungs by immunohistochemistiy using a TuJl antibody that recognizes 
the pan neuronal ~-tubulin marker. BDNF deficiency had no effect on lung branching 
morphogenesis or the expression of alpha smooth muscle actin (ex SMA) by ASM (Fig. 
1B,C). However, compared to wild type lungs, BDNF1- lungs exhibit a significant 
reduction in the outgrowth and branching of axons, as shown by TuJl immunolabeling of 
the whole left lung lobes ofE14.5 embryos and mid lung sections ofE16.5 embryos (Fig. 
3. 1 B,C). We quantified ASM innervation density by calculating the ratio between TuJ1 
immunoreactivity and cxSMA immunoreactivity in E16.5 lung sections. BDNF1-lungs 
had ~50% reduction in ASM innervation density, compared to wild type controls (Fig. 
3.1 C,D), demonstrating that BDNF is an essential target-derived neurotrophic factor for 
ASM innervation. Notably, residual innervation in BDNF1-lungs is mostly detected in 
the proximal airway where NT4 is expressed (Fig. 3.1 B), suggesting that NT4 plays a 
partially redundant role in ASM innervation ( 42). In addition, the intrinsic neurons in the 
main bronchi were not affected in BDNF1- embryos (Fig. 3.1 E). This observation 
provides further evidence that distinct signals are required for inti·insic and extrinsic 
neurogenesis in the respiratory tract, and that intrinsic neurons contribute little to ASM 
innervation in the distal lung. 
31 
A 
c 
wild 
type 
D 
>- 0 .12 
-·~ 0 .1 
(I) 
"C 0.08 
c:: 
.~ 0 .06 
-
l'a 
(: 0 .04 
(I) 2 0.02 
0 
wild type 
Figure 3.1 BDNF is essential for the innervation of ASM. 
E 
BDNF-1-
A, Immunohistochemistry to analyze the expression of the NGF family members in the 
E14.5 and El6.5 lungs. Arrows point to ASM that is immunolabeled with the BDNF or 
NT4 antibody. *marks the blood vessel in which the vascular smooth muscle expresses 
BDNF and NT4. Insert shows an enlarged blood vessel labeled with the BDNF antibody 
and endothelial cells are not labeled. Arrowheads point to ASM that is not labeled with 
the NT4 antibody. B, Whole-mount TuJl immunolabeling of axons within the left lobe of 
wild type and BDNF1- embryos at E14.5. Inserts show enlarged images of TuJl 
immunolabeling of the distal lung. C, Immunolabeling of TuJl + axons and ex SMA+ ASM 
in wild type and BDNF1- lungs at E16.5 . Arrows point to TuJl-immunoreactive axons 
that are in the proximity of the ASM. D, Quantification of ASM innervation density 
(TuJl + area/ cxSMA+ area) at E16.5. *p=0.023. E, BDNF deficiency has no effect on 
intrinsic neurons. Intrinsic neurons in the main bronchi at E16.5 were immunolabeled 
with the TuJl antibody. Similar to wild type controls, BDNF1- embryos have clusters of 
the cell bodies of intrinsic neurons (pointed by arrowheads) in the major bronchi without 
significant difference in their abundance. Scale bars, 50 f-tm. 
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3.4.2 BDNF expression is regulated post-transcriptionally. 
To determine whether BDNF expression is temporally associated with axon outgrowth, 
we analyzed BDNF protein level in the lung between E11.5 and E15.5 by Western blot 
analysis. BDNF protein is undetectable until El2.5, when aSMA expression or axon is 
also not detected in the lung mesenchyme (19,24). At E13.5 , BDNF protein is detected in 
the lung, and the level peaks around E14.5 (Fig. 3.2 A,B). Therefore, BDNF protein 
expression is temporally coordinated during ASM fmmation and initiation of axon 
outgrowth into the lung. 
The dynamics of BDNF mRNA expression differ from those of the protein in the 
developing lung. qPCR assays showed that BDNF mRNA is detectable as early as E11.5. 
The relative level of BDNFmRNA is reduced at E14.5 and E15.5 compared to earlier 
embryonic stages (Fig. 3.2 C). We confirmed BDNF mRNA expression in the lung 
mesenchyme at E12.5 and ASM at El3 .5 by in situ hybridization (Fig. 3.2 D). The 
dissociation between the time course ofBDNF protein and mRNA expression suggests 
that a post-transcriptional mechanism represses BDNF protein production prior to the 
formation of ASM and innervation. 
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Figure 3.2 Temporal expression of BDNF mRNA and protein in the embryonic lung. 
A, Analysis of the temporal expression of BDNF in the developing lung between E11.5 
and El5.5 by Western blot analysis. B, Relative levels of BDNF protein were quantified 
by normalizing to the GAPDH internal control. **p=0.007. *p=0.03. C, Temporal 
quantification of BDNF mRNA levels by qPCR using 18s mRNA as internal control. *p= 
0.04. D, In situ hybridization to detect BDNF mRNA expression in E12.5 and E13.5 
lungs. Lung epithelium is outlined by dotted lines. The sense probe was used as a control 
for background signal. n.s., not significant. 
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3. 4.3 Shh signaling promotes BDNF expression via a post-transcriptional mechanism. 
Shh signaling is required for ASM development (144,145). We assayed Shh signaling 
activity in the embryonic lung by X-gal staining of a reporter Ptcl;LacT line (146). Shh 
signaling is active in the lung mesenchyme at E12.5, before o:SMA expression, and 
persists in ASM up to El6.5 (Fig. 3.3 A) (147). Based on our finding that BDNF protein 
expression is temporally associated with ASM formation (Fig. 3.2 A), we speculated that 
Shh signaling may regulate BDNF expression. To test this hypothesis, we perturbed the 
Shh signaling activity by small molecule compounds and assessed the effect of these 
perturbations on BDNF expression in lung organ cultures. Lungs were dissected from 
E11.5 embryos and cultured in an air-media interface for 48 hr before protein and total 
RNA were extracted for Western blot analysis and qPCR. Compared to the DMSO 
control, treatment with cyclopamine (Cycl, 0.5 J.tM), which blocks Shh signaling (Fig. 3.3 
B,C), diminished BDNF protein level by more than 7-fold (Fig. 3.3 D). In contrast, 
treatment with the Shh signaling agonist SAG (1 J.tg/ml) (Fig. 3.3 B,C), increased BDNF 
protein level by 4.8-fold compared to controls (Fig. 3D). However, BDNF mRNA levels 
were not significantly affected by these treatments (Fig. 3.3 E), suggesting that Shh 
signaling post-transcriptionally induces changes in BDNF protein expression. This 
observation, together with the previous fmding of temporally dissociated BDNF protein 
and mRNA expression (Fig. 3.2), suggest that Shh signaling functions to release post-
transcriptional inhibition of BDNF expression in ASM. 
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Figure 3.3 Shh signaling post-transcriptionally activates BDNF expression in lung 
organ cultures. 
A, Shh signaling in the lung mesenchyme and ASM in the embryonic lung assayed by X-
gal staining of Ptcl ;LacZ: mouse embryos followed by immunolabeling with the a SMA 
antibody to detect ASM. Shh signaling is activated in the progenitors of ASM prior to 
aSMA expression at E12.5 and persists at E13.5 and E14.5 in the aSMA+ ASM. B-E, 
E11.5 lung cultures were cultured in the presence of DMSO as control, 0.5 f.tM 
cyclopamine (Cycl, inhibitor) or 1 [-Lg/ml SAG (agonist) for 48 hr before morphological 
and gene expression analysis. Cyclopamine and SAG differentially affects lung 
branching morphogenesis in B and mRNA expression of Shh target genes in C. BDNF 
protein and mRNA expression in lung explants were analyzed by Western blot analysis in 
D and qPCR in E, respectively. 
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3.4.4 Shh signaling inhibits miR-206 expression. 
To characterize downstream effectors of the Shh pathway that regulate gene expression at 
a posttranscriptional level, we performed miRNA profiling with control and 
cyclopamine-treated embryonic lung explants. miRNAs are small non-coding RNAs that 
suppress gene expression by inducing cleavage and/or translational repression of mRNAs 
after binding to mRNAs through their seed sequences (148). In the context of our 
findings, we sought to identify miRNAs that are up-regulated by cycloparnine treatment. 
Five miRNAs were identified in our screen (Table 3.1). Among these five, rniR-206 was 
the only rniRNA that is conserved across species and has BDNF as one of its predicted 
gene targets. Therefore, we selected miR-206 for further analysis. We confirmed that the 
miR-206 level is regulated by Shh signaling in lung explants by qPCR (Fig. 3.4 A). 
Consistent with the results of miRNA array, cyclopamine treatment increased miR-206 
levels by ~8-fold, while SAG reduced miR-206 expression by ~4-fold in cultured lung 
explants (Fig. 3.4 A). 
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miRNA Fold of change 
miR-125b-3p 2.11 
miR-694 4.44 
miR-206 7.51 
miR-697 8.26 
miR-764-SQ 9.23 
Table 3.1 miRNAs whose expression was induced by cyclopamine treatment in lung 
organ cultures. 
Embryonic lung organ cultures were treated with DMSO control or 0.5 f!M cyclopamine 
for 48 hr followed by RNA isolation and miRNA profiling. miRNAs with more than 2-
fold increase in expression by cyclopamine and greater with a p<0.05 were considered 
significant. 
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Figure 3.4 Shh signaling represses miR-206 expression. 
A, Quantification of miR-206 level in lung explants that were treated with DMSO 
control, cyclopamine (Cycl) or SAG by qPCR. **p<O.Ol. B, In situ hybridization to 
detect miR-206 expression in the embryonic lungs at E12.5, E13.5, and E15.5. Images 
show miR-206 signal after 4 hr color development at 37°C. Insert in the E15.5 image 
shows miR-206 signal in the lung mesenchyme after additional overnight color 
development. The scale bar, 50 f.tm. C, qPCR to assay rniR-206 expression in sorted 
GFP+ cells and control GFP- cells from lungs of cxSMA-hrGFP transgenic mice at E13 .5 
and El5.5. D, qPCR to assess the expression of Glil and Patched 1, two target genes of 
Shh signaling, and miR-206 in the lung ofDermol-Cre;Rosa(SmoM2) embryos at E14.5. 
Littermates that were DermorCre-were used as controls. *p=0.03. **p=0.007. 
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To test whether Shh signaling regulates miR-206 expression in vivo, we first assessed 
whether miR-206 is expressed in the lung mesenchyme by in situ hybridization. The 
specificity of the miR-206 antisense probe was validated by detection of specific signals 
in tissues that are previously shown to express miR-206 (skeletal muscle, neural tube and 
sensory ganglion) (140,149). Utilizing similarly stringent in situ conditions, we detected 
miR-206 in the lung mesenchyme between El2.5 and E15 .5 (Fig. 3.4 B). miR-206 was 
hardly detectable at E15.5, compared to E12.5 (Fig. 3.4 B), suggesting that miR-206 
expression is reduced at E15.5. miR-206 expression in the lung mesenchyme at E15.5 
became evident after an extended period of detection (inseti, Fig. 3.4 B). 
To further prove that miR-206 is preferentially expressed by lung mesenchyme, we 
performed a second assay using purified cells from the embryonic lung of an ocSMA-
hrGFP transgenic mouse that selectively expresses a green fluorescent protein (hrGFP) 
under the control of a rat ocSMA promoter (139). Using this mouse, we sorted the GFP+ 
cells from the lung ofE13.5 and E15 .5 embryos by flow cytometry. As an internal 
control, the CD31-;CD45-;GFP- population was also collected. Cells from the whole litter 
were pooled, and qPCR was performed with extracted total RNA. Consistent with our in 
situ hybridization results, miR-206 was found to be preferentially expressed in the lung 
mesenchyme compared to negative internal controls (Fig. 3.4 C); thereby providing 
further evidence for an interaction between Shh signaling and miR-206 expression. 
Notably, the rniR-206level in aSMA-GFP+ cells was ~20-fold lower at E15.5 than E12.5 
(Fig. 3.4 C), while BDNF protein expression had an opposite temporal change (Fig. 3.2 
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A), consistent with a role ofmiR-206 in post-transctiptional silencing ofBDNF gene 
expressiOn. 
To further demonstrate that Shh signaling blocks miR-206 expression in vivo, we 
analyzed changes in miR-206levels in a Dermo1-Cre;Rosa(SmoM2) mouse line. SmoM2 
contains a W539L point mutation, and upon Cre-mediated excision of a stop fragment in 
the Rosa(SmoM2) allele, Shh signaling is constitutively active in a ligand-independent 
manner (150). By crossing with a Dermo1-Cre line (151), Shh signaling is activated in 
the lung mesenchyme ofDermo1-Cre;Rosa(SmoM2) embryos. We analyzed changes in 
' 
expression ofShh signaling target genes and miR-206 at E16.5 in mutant lungs, a time-
point when endogenous Shh signaling activity is reduced in control lungs compared to 
earlier stages (147). A large majority ofDermo1-Cre;Rosa(SmoM2) embryos die before 
E16.5. Among the few that survived, qPCR analysis showed that Gli1 and Patched1 
mRNA levels were increased in the mutant lung (Fig. 3.4 D), confirming hyperactive Shh 
signaling. miR-206 levels were significantly reduced by 3-fold in these mutant lungs 
compared to Rosa(SmoM2) controls (Fig. 3.4 D), providing evidence that Shh signaling 
blocks miR-206 expression in vivo. 
3.4.5 miR-206 directly represses BDNF expression in the ASM to affect innervation. 
A direct role for miR-206 in suppressing BDNF gene expression was tested by luciferase 
assay. We cloned a ~1.5 kb BDNF 3'UTR fragment that includes all three predicted miR-
206 binding sites (positions 212-218,406-412 and 1305-1311, www.targetscan.org) into 
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the 3' end of the firefly luciferase eDNA. Luciferase reporter assays were performed in 
293T cells that were cotransfected with the luciferase construct and a lentiviral miR-206 
expression vector. A mutant miR-206, that has the deleted 6-bp seed sequence (rniR-
206mut) and therefore can no longer bind to mRNA, was used as a control. Compared to 
miR-206mut, miR-206 reduced the luciferase activity by 5-fold, indicating that miR-206 
is a direct post-transcriptional repressor ofBDNF expression (Fig. 3.5 A). 
To test the role ofmiR-206 in regulating BDNF expression in vivo, we compared BDNF 
mRNA and protein levels in the lungs of wild type and miR-206_1_ embryos. miR-206 
deficiency had no effect on lung morphogenesis or ASM development (140), based on 
histology and o:SMA immunolabeling (Fig. 3.5 B). However, compared to wild type 
lungs at El4.5, the level ofBDNF protein is almost doubled in miR-206_1_ lungs (Fig. 3.5 
C,D), while BDNF mRNA level is not changed (Fig. 3.5 E). This is consistent with a role 
ofmiR-206 in post-transcriptional repression ofBDNF expression. We assessed the 
effect of elevated BDNF levels on ASM innervation in miR-206_1_ embryos by 
immunolabeling. Whole-mount immunostaining of the left lobes with the TuJl antibody 
showed increased axon branching in miR-206-1-lungs, as compared to wild type controls 
·(Fig. 3.6 A). In addition, we observed significantly increased ASM innervation density at 
El4.5 quantified based on immune-labeled mid lung sections with the o:SMA and TuJl 
antibodies (Fig. 3.6 B). Further, miR-206 deficiency may affect ASM innervation by 
affecting the expression ofBDNF or other target genes. To test whether 
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A, Functional analysis of miR-206 binding sites at BDNF 3' UTR by luciferase assay. 
293T cells were transfected with the luciferase construct and a lentiviral vector to 
overexpress miR-206. miR-206 with deleted seed sequences (miR-206mut) was used as a 
control. **p=0.004. B, Immunostaining of E16.5 lungs of wild type and miR-2061-
embryos with the cxSMA antibodl C, Western blot analysis to assess changes in BDNF 
protein level in El4.5 miR-206- · lungs. GAPDH was the control for protein loading. 
Normalized BDNF levels to GAPDH loading control was shown in D. *p=0.03. E, qPCR 
to assay BDNF mRNA levels in wild type littetmates and miR-2061- lungs at E14.5 . 
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Figure 3.6 miR-206_1_ embryos exhibit increased ASM innervation that is dependent 
onBDNF. 
A, TuJl whole mount immunostaining of the left lung lobes from E14.5 wild type and 
miR-206_1_ embryos. Arrows point to axons. B, Quantification of innervation density in 
E14.5 wild type and miR-206_1_ lungs after imrnunostaining of lung sections using cxSMA 
and TuJl antibodies. *p=O.O 17. C, Confocal images of TuJI-imrnunolabeled axons in the 
right apical lung lobe of BDNP1-;miR-206+I- littermate controls and BDNF1-;miR-206_1_ 
embryos at E14.5. White arrow points to the tip of extended axons in the control distal 
lung and corresponding location in the lung of BDNF1-;miR-206_1_ embryos. 
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increases in ASM innervation in miR-2061- embryos are causally linked to elevated 
BDNF levels, we assessed the innervation defects in miR-206-1-;BDNF1- double mutant 
embryos. If miR-206 represses BDNF protein expression to affect ASM innervation, 
miR-2061-;BDNF1- embryos would exhibit similarly defective ASM innervation as 
BDNF1- embryos. Otherwise, the double mutant embryos would have a different 
phenotype from BDNF1- embtyos. Whole mount TuJl immunolabeling of the E14.5 right 
apical lobes showed that BDNF deficiency in the miR-206_1_ background diminishes 
innervation in the distal lung, a phenotype reminiscent of that of BDNF1-lungs (Fig. 3.6 
C, compared to Fig. 3.1 B). In addition, we quantified TuJl immunoreactive areas using 
compressed Z-stack confocal images. miR-2061- ;BDNF1-lungs showed a ~33% 
reduction in TuJl immunoreactivity, as compared to double heterozygous littermate 
controls at E14.5. Notably, this reduction was identical to that of BDNF1- lungs. 
Therefore, miR-206 directly represses BDNF expression to regulate ASM innervation. 
3.5 Discussion 
Our study investigates mechanisms that control ASM innervation during lung 
morphogenesis. We identified BDNF as an essential ASM-derived neurotrophic signal 
for extrinsic neurons to extend their axons into the distal lung. Further investigation 
reveals a functional interaction between Shh signaling and BDNF protein expression. 
This interaction is mediated by miR-206, a direct post-transcriptional inhibitor ofBDNF 
gene expression. In this regard, we showed that Shh signaling represses miR-206 
expression, thereby elevating BDNF protein expression levels. Our findings uncover a 
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role for Shh signaling in BDNF-dependent ASM innervation. In our model (Fig. 3.7), 
Shh signaling not only induces the specification of ASM (1,138,144,145), it also 
represses an inhibitory miR-206 to activate BDNF protein expression, which in tum 
facilitates ASM innervation. The dual roles of Shh signaling in the lung mesenchyme 
provide a mechanism to coordinate ASM formation and innervation during airway 
branching (Fig. 3.7). 
Our current study further establishes that distinct neurogenic signals are required for 
intrinsic versus extrinsic neurogenesis in the developing respiratory tract. Unlike intrinsic 
neurons that are dependent on GDNF family signals for survival and differentiation (24), 
extrinsic neurons require BDNF, and likely NT4, for axon outgrowth to innervate a large 
majority of ASM in the lung ( 42). 
Mechanisms that underlie Shh regulation ofmiR-206levels will require further 
investigation. One possibility is that Shh signaling regulates the transcription ofmiR-206. 
However, none of the transcriptional factors that are predicted to bind to the miR-206 
promoter were significantly affected by cyclopamine treatment in lung organ cultures 
(149). Therefore, it is unlikely that Shh signaling represses the transcription ofmiR-206. 
Alternatively, Shh signaling may regulate miR-206levels via post-transcriptional 
mechanisms. Two recent studies show that activation of the TGF~/BMP pathways 
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Figure 3.7 Model of coordinated ASM formation and BDNF-dependent innervation 
by Shh regulation of miR-206. 
Shh signaling induces ASM formation and lung branching morphogenesis. In addition, 
Shh signaling releases miR-206-mediated suppression of BDNF expression in the ASM, 
thereby inducing axon outgrowth. The dual roles of Shh signaling coordinate ASM 
formation and innervation in the embryonic lung. 
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triggers the binding of their downstream factors, Smads, to the miR-206 precursor, which 
in tum blocks processing of the miR-206 precursor into its mature form (152,153). These 
fmdings suggest the possibility that Shh signaling, which activates BMP signaling in the 
lung mesenchyme (154,155), may indirectly block maturation ofmiR-206. 
Results of our luciferase assays demonstrate that miR-206 directly binds to the BDNF 
3 'UTR to block BDNF expression. However, a previous study proposed an indirect role 
ofmiR-206 in silencing BDNF expression (156). In that study, over-expressed miR-206 
potently reduced BDNF protein levels in C2C 12 myoblast cells but had little effect on the 
luciferase activity (156). To explain this discrepancy, we compared BDNF 3'UTR 
sequences tested in both luciferase assays. Our study tested a 1.5 kb fragment that 
contains all 3 miR-206 binding sites, while a 1.0 kb fragment tested by the other group 
contained partial BDNF coding sequences and only one miR-206 binding site within the 
3'UTR closest to the stop codon (156). The difference in cloned BDNF 3'UTR sequences 
likely explains discrepant results between the two luciferase assays. It also suggests that 
one miR-206 binding site in the BDNF 3 'UTR may be insufficient for miR-206 
suppression. Interestingly, multiple BDNF mRNA variants are expressed due to different 
promoters, alternative splicing and multiple poly-A sites (157,158). The possibility that 
BDNFmRNA variants with differences in miR-206 binding sites at 3'UTR are 
differentially regulated by miR-206 adds further potential complexities to BDNF 
expression, regulation, and function. 
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The essential role of neurotrophins in ASM innervation during embryonic development 
may provide insights into pathogenic changes in innervation in airway diseases (70, 159). 
It has been reported that the levels ofNGF family members, such as NGF, BDNF and 
NT4, are elevated in bronchial lavage fluid of patients with inflammatory airway 
diseases, such as asthma (119,160). It is possible that changes in neurotrophin expression 
leads to alterations in ASM innervation, thereby playing a role in airway hyper-reactivity. 
If true, blockade of neurotrophin signaling may provide a novel approach to treat asthma. 
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CHAPTER 4: An NT4/TrkB-dependent increase in innervation links early-life 
allergen exposure to persistent airway hyper-reactivity 
4.1 Summary 
Asthma is an inflammatmy airway disease whose clinical hallmark is hyper-reactive 
airway smooth muscle (ASM). Children who are exposed to environmental insults often 
develop asthma into adulthood. However, little is understood about the long-term impact 
of early childhood insults on airway stmcture and function. Using a mouse model of 
ovalbumin (OVA)-induced airway allergic inflammation, we showed that OVA 
sensitization and challenge in early life led to increased ASM innervation and persistent 
airway hyper-reactivity (AHR). In contrast, OVA exposure in adult life elicited short-
term AHR without affecting the level of innervation. We found that postnatal ASM 
innervation required neurotrophin 4 (NT4) signaling through its tyrosine kinase receptor 
TrkB, and that early-life OVA exposure significantly elevated NT4/TrkB signaling to 
increase innervation. Notably, genetic dismption and small molecule blockade of 
NT4/TrkB signaling in OVA-exposed pups prevented both acute and persistent AHR 
without affecting baseline airway function or inflammation. Furthermore, biophysical 
assays using lung slices and isolated cells demonstrated that NT4 was required for hyper-
reactivity of ASM induced by early-life OVA exposure. Together, our fmdings show that 
the NT4/TrkB dependent increase in innervation plays a critical role in altering the ASM 
phenotype during postnatal growth, thereby linking early-life allergen exposure to 
persistent airway dysfunction. 
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4.2 Introduction 
Asthma is a chronic inflammatory airway disease with increasing prevalence despite 
improved treatment. It is one of the leading causes of missed days from work and school. 
Patients suffering from this disease present common symptoms of airflow obstruction, 
wheeze, and cough. In asthma, the airway smooth muscle (ASM) undergoes profound 
phenotypic changes. These include hypertrophy, hyperplasia, and notably, hyper-
reactivity in response to non-specific and specific agonists, such as methacholine ( 161 ). 
Asthma typically presents early in childhood and often continues into adulthood (162-
164 ). Clinical data indicate that 80-90% of adults with chronic asthma have disease onset 
before age 5, and there is an association between severity of symptoms in childhood and 
persistence of asthma into adult life (162). In this context, a major risk factor for asthma 
is early-life exposure to environmental insults, including aeroallergens, ozone, cigarette 
smoke, and respiratory viral infection (161,163). As the lung continues to develop 
postnatally, early-life insults could have profound, long-term effects on ai1way structure, 
function, and disease susceptibility. In support of this hypothesis, recent studies in 
rodents show that peri- and neo-natal exposure to tobacco smoke and respiratory 
syncytial virus (RSV) leads to AHR later in life whereas late, postnatal exposure has no 
such effect (122,165). These findings indicate that the immature lung is more prone to 
long-term impairment by environmental insults than the mature, adult lung. However, 
little is known about the molecular nature and mechanisms of such impairment. 
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A growing body of evidence indicates a link between alterations in aitway innervation 
and asthma. Previous studies using peri- and neo-natal rodent models showed that 
environmental insults lead to changes in innervation by neuropeptide Y- and substance P-
containing axons, and these changes are associated with increased expression of nerve 
growth factor (NGF) and brain-derived neurotrophic factor (BDNF), respectively 
(166,167). NGF and BDNF, together with NT3 and NT4, belong to a neurotrophin (NT) 
family that has established roles in controlling neural innervation of target tissues (39). In 
addition to studies in rodents, changes in airway innervation have also been reported in 
infant rhesus monkeys that were exposed to ozone and house dust mite allergen (121). 
Furthermore, human infants with acute RSV infection, a risk factor of asthma later on 
(161,165), had high levels ofNGF and BDNF in their bronchoalveolar lavage fluid (119). 
Notably, high serum levels ofNT4 are positively correlated with asthma severity in 
children (168). These observations suggest that changes in NT expression and innervation 
by early-life environmental insults are associated with airway dysfunction. 
The mammalian airway is innervated by two distinct groups of neurons: the intrinsic 
neurons, whose cell bodies are located in the main bronchi, and the extrinsic neurons, 
whose cell bodies are located outside of the lung and extend their axons into the airways 
(6,133,169). We showed previously that the intrinsic neurons are dependent on the glial 
cell-derived neurotrophic factor for ASM innervation in the main bronchi (24). Only a 
few intrinsic neurons are located in the secondary bronchi with little to none in the distal 
lung of the mice (24). In contrast, the extrinsic neurons require ASM-derived BDNF to 
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innervate ASM within the rest ofthe lung during embryogenesis ( 40). In support of our 
findings, mice deficient in TrkB, the tyrosine kinase receptor for both BDNF and NT4, 
exhibit reduced ASM innervation ( 42). The mechanisms controlling postnatal airway 
innervation, however, have not been established. 
Studies in various organs and across different species have established a paradigm that 
the cross-talk between the innervating neuron and the target tissue plays a critical role in 
shaping phenotypes of both the neuron and the target (141,170-174). Related to the 
smooth muscle phenotype, our lab showed previously in the esophagus that reduction in 
innervation embryonically results in profound impairment of smooth muscle contractility 
in adult life (141). Built upon this well-established paradigm and our fmdings regarding 
NTs in ASM innervation, we speculate that early-life environmental insults alter airway 
innervation, which in tum changes ASM phenotype, leading to persistent AHR. 
In this study, using a mouse model of allergic inflammation, we investigated how 
allergen exposure during early postnatal life affects airway function later in life. We 
demonstrate that an increase in NT4!frkB signaling functionally links early-life allergen 
exposure to persistent AHR by regulating ASM phenotype. Our findings may explain 
how early-life lung insults lead to persistent asthma into adulthood. 
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4.3 Methods 
4.3.1 Mice 
Wild type, NT4_1_ (stock number: 002497), and NG2-dsRed (stock number: 008241) mice 
were purchased from The Jackson Laboratories. The TrksF"616AIF616A (Trksf"AIFA) line was 
kindly provided by Dr. David Ginty at Johns Hopkins University (175). The aSMA-GFP 
mouse had a green fluorescent protein ( GFP) gene expressed under the control of the a-
smooth muscle actin promoter (139). All mice used were in C57BL/6J background. All 
animal studies were approved by the Boston University School of Medicine Institutional 
Animal Care and Use Committee. 
4.3.2 Neonatal allergic asthma model 
Pups were sensitized by intraperitoneal injections of 10 flg ovalbumin (OVA, Sigma, 
A5503) protein in Imject alum (Thermo Scientific, 77161) on postnatal day 5 (P5) and 
P10 followed by three 10-minute challenges with 3% aerosolized OVA solution on P18, 
P19, and P20. Control pups were challenged with PBS. Mice were subjected to 
physiological assessment of airway function by using the FlexiVent apparatus (SciReq) 
on P21. To block TrkB signaling in Trksf"AIFApups, 10 fll1NMPP1 (25 f.!M) in 2% 
ethanol were delivered by intraperitoneal injection, while controls received 2% ethanol 
(175). For studies on TrkB-dependent postnatal lung innervation, pups received daily 
1NMPP1 injection up to P14. To block over-activation ofTrkB in OVA-exposed pups 
without affecting normal basa1level of TrkB signaling, Trksf"AIFA pups received daily 
lNMPPl injection between Pll and P20. A subset of OVA-exposed WT andNT4_1_ pups 
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was allowed to grow into adulthood followed by physiological and histological assays at 
8 weeks of age. 
4.3.3 Adult acute allergic asthma model 
Adult mice at three months of age were sensitized by intraperitoneal injections of OVA 
protein (50 IJ.g) in alum on days 0 and 7. Mice were challenged with aerosolized 2% 
OVA solution for 20 minutes on days 14, 15, 16, 17, and 18. Control mice were 
sensitized with OVA followed by challenge with aerosolized PBS. Mice were analyzed 
on day 19. For the persistence group, mice were analyzed 2.5 weeks (18 days) after last 
challenge. 
4.3.4 Physiological measurement of airway reactivity 
Measurement of airway resistance by FlexiVent was performed as described ·previously 
(176). Briefly, mice were anesthetized, cannulated, and ventilated using the FlexiVent 
ventilator (Scireq Scientific Respiratory Equipment). Baseline airway resistance was 
measured after airway delivery of nebulized vehicle, and similar measurements were 
performed at increasing concentrations of nebulized methacholine (5 mg/mL, 15 mg/mL, 
25 mg/mL). Data are presented as normalized to baseline level. After final measurements, 
each mouse was disconnected from the ventilator for organ and body fluid harvest. 
4.3.5 ELISA 
Blood and bronchoalveolar lavage fluid were collected from pups after physiological 
measurement on P21. OVA-specific IgE levels in serum were measured using an ELISA 
kit (Md.BioProducts M036005) following manufacturer's protocol. IL-13 levels in 
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bronchoalveolar lavage fluid were assayed using an ELISA kit (Life Technologies, 
KMC2221) following manufacturer's protocol. 
4.3.6 Histology, aSMA staining and quantification 
The left lung lobes were harvested, fixed, and embedded in paraffm. Serial sagittal 
sections (5 f.tm) in the middle of the lobe were collected. Four sections were treated with 
xylene to remove paraffin and rehydrated in ethanol followed by PBS washes. For mucin 
staining, sections were processed with the Periodic acid-schiff (PAS) staining system 
(395B-1KT Sigma Aldrich) following the manufacturer's protocol. For immunostaining 
with an antibody against a-smooth muscle actin (cxSMA) (1 :100, MS-113, Thermo 
Scientific), primary antibody was applied for 2 hours at room temperature. Antigen-
antibody complexes were detected by DAB, counterstained with hematoxylin, and 
mounted in polymount. Medium-sized airways were imaged with 40x bright field 
microscopy (Zeiss Axioskop 40). Image J was used to quantify the cxSMA immune-
reactive area and the length of the basement membrane. The cxSMA density was then 
calculated by dividing the cxSMA+ area by the length of the basement membrane. A 
minimum of 12 airways from 3 mice, 4 airways per mouse, were quantified and averaged 
for each treatment group. 
4.3. 7 Fluorescent labeling and confocal microscopy 
The right apica1lobe of the lung was collected and fixed in 4% paraforma1dehyde in PBS 
at 40C overnight. After cryoprotection in 30% sucrose in PBS, 50 f.tm sections were 
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collected along the rostral-caudal axis ofthe lobe. Four sections, 1 mm apart, were 
immunostained using a previously described protocol ( 40) and mounted with 
Fluoromount-G (eBioscience). Primary antibodies included biotinylated mouse anti-
neural class III ~-tubulin (TuJl, 1:200, R&D, BAM1195) and mouse anti-CORP (1 :1000, 
Sigma C8198). Antigen-antibody complexes were detected by fluorescence. After 
staining, sections were imaged using a Zeiss Axiovert 1OOM LSM 510 equipped with an 
Argon and 2 HeNe lasers (Thornwood, NY). Compressed z-stack confocal images were 
presented and quantified. To determine the innervation density, the TuJl or CGRP 
immune-reactive area was quantified and then divided by the area of each airway using 
Image J. Ten medium sized airways were imaged and quantified per slide for a total of 
forty airways per mouse. These numbers were then averaged per mouse and for each 
treatment. 
4.3.8 Western blot analysis 
Protein samples were collected from right basal lung lobes after homogenization in RIP A 
buffer containing proteinase inhibitor (Roche Diagnostics). Protein concentration of 
whole lung lobe homogenate was determined using the BCA protein assay (Thermo 
•· I 
Scientific). Western blot analysis for protein samples (20 j.lg) was performed as described 
previously (40). Primary antibodies included: rabbit anti-NF(H&M) (1:1000, Millipore 
MAB 1592), rabbit anti-NF(H) (1 :2000, Millipore AB 1991 ), rabbit anti-BDNF (1: 100, 
Santa Cruz 546 N-20), rabbit anti-NT4 (1 :100, Santa Cruz 545 N-20), mouse anti-
GAPDH (1:100,000, Abeam ab8245), mouse anti-phosphorylated TrkB (1:500, Abeam 
ab52191). Antigen-antibody complexes were detected with SuperSignal West Pico 
57 
Chemiluminescent Substrate (Thetmo Scientific) and exposed on film. Densitometry 
units of individual protein bands were measured by Image J and were nmmalized to 
GAPDH levels or total protein levels for each sample. 
4.3.9 In situ hybridization 
In situ hybridization was performed on 15 f.!m frozen sections using digoxigenin-labeled 
antisense RNA probe) using an established protocol (141). The in situ probe for a lung 
epithelium marker CCI 0 was kindly provided by Dr. Wellington Cardoso at Boston 
University School ofMedicine (177). To generate in situ probes for TrkB mRNA, a 126 
bp eDNA PCR fragment was cloned into pGEM-T easy vector (Promega) followed by T7 
and SP6 transcription. Primers used to clone the TrkB eDNA fragment follow: 
TrkB forward: 5'-AGACATTTCCGCCACCTTGAC-3' 
TrkB reverse: 5'-CACAGACTTTCCTTCCTCCACG-3'. 
4.3.10 Quantitative real-time PCR (qPCR) 
Left basal lung lobes and brain were collected and homogenized for total RNA isolation 
using the RNeasy Mini Kit (Qiagen). Total RNA (1 f.!g) was reverse transcribed using 
SuperScript III First-Strand Synthesis SuperMix (Invitrogen). qPCR was perfmmed using 
the Power SYBR Green PCR Master Mix (Applied Biosystems) on a StepOnePlus Real-
Time PCR System (Applied Biosystems). The relative level ofmRNA expression was 
calculated by nmmalizing to the housekeeping gene, fJ-actin , mRNA using ~Ct (cycle 
threshold difference). Primers for qPCR follow: 
p75 forward:5'-CAGACGATGCCGTGTGCCGA-3' 
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p75 reverse: 5'-CAGGGCGTGCACTCGCGTAA-3' 
TrkB forward: 5'-ATTCACCACCGAGAGTGACG-3' 
TrkB reverse: 5' -TCTTCCTTGTGTGTGGTTCC-3' 
fJ-actin forward: 5 ' -GCAGCTCCTTCGTTGCCGGT -3' 
fJ-actin reverse: 5;-TACAGCCCGGGGAGCATCGT-3'. 
4. 3.11 Flow cytometry and cell sort 
Cell suspensions were obtained by digesting lungs with 0.1% collagenase A (Roche 
Diagnostics), 2.4 units/ml Dispase (Roche Diagnostics), and 6 units/ml DNase I (Qiagen) 
as described previously (178). For flow cytometry, cell suspensions were incubated with 
the following antibodies: CD3-FITC (1:100), CDllb-FITC (1:100), CD13-PE (1:50), 
Ly6G-FITC (1:50), B220-PE (1:200), CDllc- PerCP-Cy5 (1: 100), CD45-FITC (1 :200), 
CD45-PE (1 :200), CD45-PE (1 :200), CD45-PerCP-Cy5 (1 :200). After incubation for 30 
minutes at 40°C, cells were washed with PBS before sorting on a LSRJI flow cytometer 
(BD Biosciences). To isolate ASM cells by cell smiing, lung cell suspensions were 
prepared from aSMA-GFP;NG2-dsRed mice and NT4_1_; aSMA-GFP;NG2-dsRed pups 
that were challenged with PBS or OVA. Cells were stained with CD31 (1: 150) and CD45 
(1 :200) antibodies. To exclude dead cells, cells were incubated with a viability dye 
( efluor 450, 1 :200, eBioscience) prior to immunostaining. Live ASM cells ( efluor-CD45-
CD31-hrGFP+ dsRed-) were collected based on their singly high GFP levels using a Moflo 
cell sorter (Beckman Coulter, Fullerton, CA). Cells with relatively low GFP levels, which 
likely were lung myofibroblasts, were not collected. All antibodies were purchased from 
BD Pharmingen. 
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4.3.12 Lung slice preparation and measurement of airway contraction 
Precision cut lung slices were prepared as described previously (179). Briefly, the mouse 
lungs were inflated with 1% low-melting point agarose in HBSS. After the agarose 
solidified, the two largest lobes were separated and sectioned into 200 J.ilil thick slices 
using a Precisionary Instruments VF-300 tissue slicer. Lung slices were cultured in 1:1 
DMEM/F-12 supplemented antibiotics (Invitrogen, MA, USA). Media was changed once 
an hour for the first 4 hours to remove melted agarose and then maintained overnight. 
Next day, lung slices were secured in place within a standard 12 well culture plate using a 
ring of nylon mesh together with a metal washer. The multi-well plate was imaged using 
an inverted microscope (Leica Microsystems, DMI6000B). Lung slices were pre-treated 
with Isoproterenol (30 j..LM, Sigma Aldrich) to induce relaxation followed by stimulation 
with 10-7M, 10-6M, 10-5M, and 10-4M methacholine (Sigma Aldrich). Mid-sized 
airways with a baseline luminal area between 14,000 -20,000 j..Lm2 were assayed. Each 
airway was imaged every minute for a total duration of 35 minutes. From the acquired 
images, we quantified airway luminal area (Image J, NIH), and normalized its magnitude 
to the pre-treatment baseline value. 
4.3.13 Cell contractility-traction force microscopy 
Isolated GFP+ ASM cells from PBS-treated and OVA-exposed aSMA-GFP;NG2-dsRed 
andNT4_1_; aSMA-GFP;NG2-dsRedpups were cultured sparsely on collagen-1 coated 
polyactylamide gel substrates (stiffness is 4 kPa). Embedded in the substrate were 
fiducial markers consisting of fluorescent nanobeads. By tracking deformation of the 
beads, and solving the inverse problem of forces necessaty to induce those displacements, 
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we quantified the contractile forces (called tractions) that cells exert on their substrate 
using MATLAB (180,181). From the traction map, we extracted a single measure of 
overall cell contraction called the contractile moment ( 180). 
4.3.14 Statistics 
All data are represented as means ± s.e.m. from a minimum of 3 separate experiments. 
Airway resistance data and contraction assays using lung slices were compared between 
genotypes, treatment, and methacholine doses using two-way, repeated-measures 
ANOV A model with mouse type, methacholine dose and their interaction as predictors. 
The model was developed as a general linear model for correlated data using an 
unstructured covariance so that no assumptions were made about the shape of the profile 
over methacholine dose or the covariance structure between repeated measurements. The 
main test of interaction assessed whether the pattern of responses over methacholine dose 
differed between mouse types. If this test was significant at the a=.1 level, then specific 
comparisons were made using contrasts between mouse genotype types at each of the 
methacholine doses. Statistical analyses for western blot analyses, immunohistochemistry 
quantification, and ELISAs were performed by two-tailed Student's t test. *p<0.1. 
**p<0.05. ***P<O.Ol. 
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4.4 Results 
4.4.1 OVA exposure in early-life, but not in adulthood, leads to persistent AHR. 
To evaluate the impact of early-life allergen exposure on the airway, we created a 
neonatal mouse model by sensitizing C57BL/6 pups to OVA allergen at postnatal day 5 
(P5) and P10 followed by three aerosolized OVA challenges between P18-P20 (Fig. 4.1 
A). Mice were analyzed at P21 when the airway begins to take a mature configuration 
(182) . Compared to saline (PBS)-challenged pups, OVA-challenged pups displayed key 
features of asthma: ASM thickening (Fig. 4.1 B and C), AHR in response to 
methacholine (Fig. 4.1 D), over-production of mucin (Fig. 4.1 E), infiltration of immune 
cells, and increased serum levels of OVA-specific IgE (Fig. 4.1 F). Notably, OVA-
exposed pups had persistent AHR after they reached adulthood at eight weeks of age 
(P21---+adult) (Fig. 4.1 G) despite diminished inflammation and ASM thickening (Fig. 4.1 
Hand I). 
To test if OVA exposure in adult life also leads to persistent AHR, 3-month-old mice 
were sensitized and challenged with OVA (Fig. 4.2 A) (176). 24 hours after the last 
challenge, compared to PBS-challenged controls, OVA-challenged adult mice exhibited 
AHR (Fig. 4.2 B) and other key features of asthma (data not shown) (176). However, 
AHR resolved completely 18 days after the last challenge (adult---+ 2.5 weeks recovery) 
(Fig. 4.2 C). These observations confirm that the developing lung is more prone to long-
term functional impairment by insults than the mature, adult lung (122,165). 
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Figure 4.1 A neonatal asthma model induces persistent airway hyper-reactivity. 
A. Experimental protocol to induce allergic ai1way inflammation by OVA in a neonatal 
mouse model. Controls received saline (PBS) challenges. B. Representative image of 
aSMA imrnunostaining in the aitways of PBS- and OVA-exposed pups at P21. Arrows 
point to aSMA+ ASM. *denotes blood vessels also labeled with the ocSMA antibody. C. 
Quantification of aSMA density in the aiiWays of PBS- and OVA-exposed pups at P21. 
D. Aitway reactivity of controls (n=14) and OVA-exposed pups (n=13) was assessed at 
P21 by measuring aitway resistance using the FlexiV ent apparatus with increasing 
concentrations of methacholine. E. Representative images of mucin staining in the 
aiiWays of PBS- and OVA-exposed pups at P21. Arrows point to mucin+ staining. F. 
Serum levels of OVA-specific IgE in PBS- and OVA- exposed pups at P21, measured by 
ELISA. The line represents the average of IgE levels in serum of OVA-exposed pups. G. 
Controls (n=9) and OVA-exposed pups (n=13) were allowed to grow for 5 weeks into 
adulthood. AiiWay resistance was measured using the FlexiVent apparatus at 8 weeks of 
age. H. Representative image of aSMA imrnunostaining in the aitways of 8-week-old 
adult (P21-7adult) mice that were previously exposed to PBS and OVA as neonates. 
Arrows point to aSMA+ ASM. *denotes blood vessels also labeled with the ocSMA 
antibody. I. Quantification of ocSMA density in the aitways of P21-7adult mice. *p<O.l; 
**p<0.05; ***p<O.Ol. Scale bars, 50 J..Lm. 
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4.4.2 OVA exposure in early-life, but not in adulthood, leads to increases in ASM 
innervation. 
We thus utilized the OVA-exposed pups as a model to investigate how early-life allergen 
exposure affects long-tetm airway structure and function. In these mice, persistent AHR 
occurred without sustained ASM hyperplasia (Fig. 4.1 G-I), suggesting persistent 
changes in the ASM phenotype that is independent of changes in ASM cell mass. Since 
ASM is innervated and neural innervation plays an important role in shaping the 
phenotype of target tissues, we hypothesized that early-life allergen exposure may affect 
ASM innervation, ultimately leading to a change in the ASM phenotype. To test this, we 
measured ASM innervation levels in OVA-exposed pups at P21 and after they grew into 
adulthood. Western blot analysis showed that early-life OVA exposure significantly 
increased the level of neurofilament (NF, high and medium molecular weight, H&M) by 
two-fold (Fig. 4.3 A and B). Because ASM is the major target of innervation in the 
mouse lung, we concluded that early-life OVA exposure led to elevated ASM 
innervation. Consistently, intmunostaining for neural tubulin III (TuJ 1) showed that 
OVA-exposed lungs had more axons and a higher ASM innervation density than controls 
at P21 (Fig. 4.3 C and D). Similar increases in ASM innervation were also observed in 
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Figure 4.2 An acute adult asthma model shows transient airway hyper-reactivity. 
A. Experimental protocol to induce acute asthma in adult mice. Control mice received 
PBS challenges. B. Airway reactivity of controls (n=8) and OVA-challenged adult mice 
(n=5) was assessed at Dl9 by measuring airway resistance using the FlexiVent apparatus. 
C. Airway reactivity of controls and OVA-exposed mice was assessed 2.5 weeks (18 
days) after last challenge. Each group included 5 adult mice. Data shown in (B) and (C) 
were normalized to baseline resistance of PBS-challenged control mice. *p<O. l; 
**p<0.05. 
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pups exposed to cockroach allergen (data not shown). In contrast, OVA-exposed adult 
mice had no change in lung innervation levels after the last OVA challenge as assayed by 
Westem blot analysis (Fig. 4.3 G and H). These data show that allergen exposure elicits a 
distinct neurogenic response in the developing postnatal lung. 
To test whether increased innervation after early-life OVA exposure persisted, we 
assessed the airway innervation in mice exposed to OVA as neonates after they grew into 
adulthood (8 weeks of age; P21----+adult). We found that although the overall airway 
innervation in these mice was no longer higher than control mice, sensory afferents 
marked by calcitonin-gene related peptide (CGRP) expression remained more abundant 
(Fig. 4.3 E and F). 
4.4.3 NT4-activated TrkB signaling is required for ASM innervation in the postnatal 
lung. 
To understand how early-life OVA exposure increased ASM innervation, we first 
characterized how the lung normally becomes innervated in postnatal life. Using 
TuJlimmunostaining and Westem blot analysis for NF(H&M), we showed that ASM 
innervation increased postnatally and peaked around P14 (Fig. 4.4 A, Band D). Next, we 
sought to identify the key signals for postnatal ASM innervation. We focused on the NGF 
family because we previously showed that ASM expresses BDNF and NT4, two NTs that 
both signal through the TrkB receptor (39), and that extrinsic neurons require BDNF-
activated TrkB signaling for axon extension to innervate the ASM during embryogenesis 
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Figure 4.3 Early-life OVA exposure increases ASM innervation. 
A . . Western blot analysis of NF (H&M) in lung homogenates collected at P21 from 
controls and OVA-exposed pups. B. Densitometry analysis of NF(H&M) signal in 
western blot assay in (A). Data were normalized to the total amount of loaded protein. C. 
TuJl immunolabeling in airways of control and OVA- exposed pups at P21. Arrows 
point to TuJl-labeled axons. TuJI immuno-reactivity was normalized to the size of each 
airway to calculate innervation density. D. Innervation density in controls and OVA-
exposed pups at P21. A total of forty airways from ten pups of each group were analyzed. 
E. Immunostaining for calcitonin gene-related peptide (CGRP) in the airways of 8-week-
old adult mice that were previously exposed to PBS or OVA as pups (P21 ~adult). 
Arrows point to CGRP-containing sensory afferents. F. Quantification of CGRP staining 
in the airways ofP21 ~adult mice by normalizing CGRP immuno-reactivity to the size of 
the airway. A total of fmiy airways from ten pups of each group were analyzed. G. 
Western blot analysis ofNF(H) in lung homogenates of adult mice that were challenged 
with PBS or OVA. Lungs were harvested at D19. H. NF(H) levels were quantified by 
normalization to GAPDH levels. Data represent the average of four separate experiments 
with a minimum of three mice per group for each experiment. Scale bars, 50 )liD. *p<O.l; 
***p<O.Ol. 
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(40,42). Western blot analysis showed that BDNF levels were greatly reduced after birth, 
whereas NT4 expression increased postnatally and peaked at Pl4 (Fig. 4.4 C and D), 
coinciding with the maturation and completion of postnatal lung innervation (Fig. 4.4 B 
and D). 
To investigate the role ofNT4 in postnatal lung innervation, we compared NF(H&M) 
levels between wild type (WT) and NT4_1_ mice at E18.5 and P21. NT4_1_ mice have minor 
neural defects but are otherwise viable and fertile and show normal airway structure (Fig. 
4.4 A) (183). At E18.5, we found no change in airway innervation levels in NT4_1_ mice 
(Fig. 4 E and F), further supporting BDNF as the key neurogenic signal in embryonic 
lung (40). However, at P21, NT4_1_ pups showed a 2-3 fold reduction in NF(H&M) levels 
and decreased TuJl immuno-reactivity as compared to WT pups (Fig. 4.4 G and H), 
indicating that NT4 is required for postnatal ASM innervation. To validate this 
observation, we blocked signaling from NT4 receptor TrkB by treating Trkff616AJF616A 
(TrkffAIFA) pups with a phosphatase inhibitor, lNMPPl, and assessed changes in ASM 
innervation. TrkffA!FA mice harbor a point mutation in the TrkB kinase domain that 
renders the receptor susceptible to specific inhibition by 1NMPP1 (175). This inhibition 
is reversible in vivo, and without 1NMPP1 treatment, TrkffA!FA mice are normal (175). 
We found that daily intranasal 1 NMPP 1 delivery from P 10-16, a period when lung 
innervation is maturing, resulted in approximately 40% reduction in NF(H&M) levels in 
the lungs ofP21 TrkffA!FA mice compared to vehicle-treated Tr~AJFA mice (Fig. 4.4 I 
and J). These results show that NT 4-activated TrkB signaling is essential for ASM 
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Figure 4.4 NT 4-activated TrkB signaling is required for ASM innervation 
postnatally. 
A. Representative images of TuJl labeled lung sections from wild type mice pre-birth 
(El8.5) and at P7, Pl4 and P21. TuJl staining of lung sections from NT4·!- and lNMPPl-
treated TrkffAIFA pups at P21 was also shown. Anows point to TuJl -labeled axons in the 
airway. Scale bars, 50Jl1Il. B. Western blot analysis NF(H) levels in the lungs of pups at 
P7, Pl4 and P21. C. Western blot analysis ofBDNF and NT4levels in the lungs at El8.5, 
P7, Pl4, and P21. D. Densitometry analysis ofNF(H), BDNF, and NT4 levels at El8.5 
and during postnatal development, as shown in (B) and (C). Signals were normalized to 
GAPDH levels. E. Western blot analysis of NF(H&M) levels in El8.5 whole lung 
homogenates ofWT and NT4_1_ pups. NF(H&M) signals were quantified by densitometry, 
normalized to GADPH levels, and shown in (F). G. Western blot analysis of NF(H&M) 
levels in P21 whole lung homogenates of WT and NT4_1_ pups. NF(H&M) signals were 
quantified, normalized, and shown in (H). I. Western blot analysis ofNF(H&M) levels in 
P21 lungs of TrkffAIFA mice treated with lNMPPl or vehicle control. NF(H&M) signals 
were quantified, normalized to GADPH levels, and shown in (J). *p<O.l; **p<0.05. 
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innervation in postnatal lungs. 
To rule out the possibility that deficient NT4/TrkB signaling directly affects postnatal 
ASM fonnation, we assessed TrkB expression in the lung at P21 by in situ hybridization. 
The mRNA expression of CCI 0, a lung epithelium marker was used as a positive control 
(Fig. 4.5 A). TrkB expression was found in neural cell bodies located in the peripheral 
sensory ganglia, a known source of extrinsic innervation for ASM (Fig. 4.5 A) 
(6,169,184). However, no TrkB mRNA was detected in the ASM or any other lung cells 
(Fig. 4.5 A and 4.7 B) (75,185). TrkB mRNA was also not found in ASM-innervating 
axons (Fig. 4.5 A), although TrkB receptor functions in these axons (Fig. 4.4). This 
observation is consistent with current data showing that only a select group of mRNA 
transcripts are localized in distal intra-axonal compartments at extremely low abundance 
(186). The lack of TrkB mRNA expression by ASM indicates that NT4 deficiency and 
blockade ofTrkB signaling have no direct effect on ASM. Consistently, ASM cells in 
lungs of NT4_1_ pups and INMPP !-treated TrkffA!FA pups showed normal expression of 
aSMA (Fig. 4.5 B). These findings indicate that NT4-activated TrkB signaling is required 
for postnatal lung innervation but not ASM formation. 
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Figure 4.5 Deficiency of NT4 or TrkB signaling has no effect on postnatal ASM 
formation. 
A. In situ hybridization for TrkB mRNA expression in the lungs at P21. The sense probe 
served as a negative control. TrkB mRNA was not found in the lung, but was detected in 
the cell bodies of sensory neurons in the dorsal root ganglion (DRG) that extend their 
axons to innervate the lung. As a positive control for TrkB in situ in the lung, CCI 0 
mRNA expression was detected in the lung epithelium. B. Lung sections from WT, NT4_1_ 
and INMPPI-treated TrkffAIFA pups were immunolabeled with an <XSMA antibody at 
P21. Arrows point to aSMA+ staining of the airway. *denotes blood vessels also labeled 
with <XSMA antibody. Scale bar, 50 11m. 
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4. 4. 4 Early-life OVA exposure elevates NT4/TrkB signaling to increase ASM innervation. 
To test whether early-life OVA exposure alters NT4/TrkB signaling to increase ASM 
innervation, we compared the levels ofNT4 expression and TrkB signaling in the lungs 
of control and OVA-exposed pups by Western blot analysis. We found that OVA-
exposed pups had a 5-fold increase in NT4 protein expression (Fig. 4.6 A) and a 2-fold 
increase in TrkB phosphorylation, indicative of receptor activation (Fig. 4.6 B). We then 
assessed the effect of elevated NT4/TrkB signaling on ASM innervation in OVA-exposed 
pups. For this, we sensitized and challenged NT4_1_ pups (described in Fig. 4.1 A) and 
analyzed changes in lung innervation at P21. In contrast to increased innervation in 
OVA-exposed WT pups, allergic airway inflammation had no effect on the low basal 
levels of ASM innervation in NT4_1_ pups (Fig. 4.6 C and D). lNMPPl intranasal 
treatment of TrkffA!FA pups between Pll-P20 also prevented OVA- induced increases in 
ASM innervation without affecting normal levels of innervation density, as assayed by 
TuJl immunohistochemistry (Fig. 4.6 E). These findings demonstrate that early-life OVA 
exposure increased ASM innervation by elevating NT 4-activated TrkB signaling. 
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Figure 4.6 NT4-activated TrkB signaling is required for OVA-induced increase in 
lung innervation. 
A. NT4 levels in the lungs of controls and OVA-exposed pups at P21 analyzed by 
Western blot analysis and normalized to GAPDH levels. B. Western blot analysis of 
activated TrkB by phosphorylation in controls and OVA-exposed lungs. C. Western blot 
analysis ofNF(H&M) at P21in WT and NT4_1_ pups that were exposed to PBS and OVA. 
NF(H&M) signals were juantified by densitometry and nonnalized to GAPDH levels in 
(D). E. WT and Trkff 'FA pups were exposed to PBS or OVA. TrkeF'AIFA pups also 
received short-term INMPPI treatment to prevent OVA-induced over-activation ofTrkB 
signaling. The innervation density in the lungs of each group was analyzed by TuJl 
immunolabeling. Graphs represent an average of forty airways from ten pups of each 
group. 
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4.4.5 NT4 deficiency has no effect on OVA-induced airway inflammation. 
To test whether deficient NT4/TrkB signaling affects inflammation, we examined TrkB 
mRNA expression during allergic aitway inflammation in OVA-exposed pups by in situ 
hybridization. No TrkB mRNA was detected in OVA-exposed lungs (Fig. 4.7 A). To 
validate this finding, we performed qPCR using CD45+ immune cells and GFP+ smooth 
muscle cells isolated from the lungs of aSMA-GFP pups (139). For this, aSMA-GFP 
pups were subjected to OVA sensitization and challenges prior to cell sorting. Consistent 
with the results of in situ hybridization, qPCR did not show that immune cells and ASM 
cells expressed detectable levels of TrkB or p75, a low affinity receptor for all NTs, as 
compared to El8.5 brains (Fig. 4.7 B) (75,185). These findings rule out the possibility 
that NT4 deficiency affects the immune response and ASM directly. We also compared 
the levels of the key Th2 cytokine, IL-13, in the lungs ofWT and NT4_1_ pups at P21. We 
found that compared to WT pups, NT4_1_ pups had a normal basal IL-13 level and showed 
a similar, significant increase in IL-13 levels after OVA exposure (Fig. 4. 7 C). 
Furthermore, OVA-exposed NT4_1_ pups had elevated serum levels oflgE, similar to WT 
pups (Fig. 4.7 D). Lastly, flow cytometry analyses showed no difference in OVA-induced 
lung infiltration of immune cell types between WT and NT4_1_ pups (Fig. 4. 7 E). 
Together, these results indicate that deficient NT4/TrkB signaling has no effect on OVA-
induced allergic airway inflammation. 
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Figure 4.7 Deficient NT4 signaling has no effect on OVA-induced airway 
inflammation. 
WT and NT4·I- pups were sensitized and challenged with OVA. The expression of TrkB 
mRNA and OVA-induced inflammation were assessed in the lungs at P21. A. In situ 
hybridization to detect TrkB mRNA expression in OVA-exposed lungs of WT pups. The 
antisense probe for CCI 0 mRNA expression was the positive control. Scale bars, 100 
J..Lffi. B. qPCR analysis of TrkB and p75 mRNA levels in isolated smooth muscle cells and 
immune cells from the lungs of aSMA-GFP pups that were exposed to PBS or OVA. 
CD45+ immune cells and CD45-CD31-GFP+ smooth muscle cells were isolated by flow 
cytometry. Total RNA from the brain of El8.5 embryos was used as a positive control. 
Data were normalized to .13-actin mRNA levels. C. IL- 13 levels in bronchoalveolar 
lavage of WT and NT4_1_ pups that were exposed to PBS or OVA, assayed by ELISA. D. 
Serum levels of OVA-specific IgE in PBS- and OVA-exposed NT4_1_ pups at P21 , 
measured by ELISA. The line represents the average of IgE levels in serum of OVA-
exposed NT4·I- pups. E. Flow cytometry analysis of immune cells in the lungs of WT and 
NT4_1_ mice that were exposed to PBS or OVA. To represent the increase in immune cell 
infiltration after OVA exposure to pups of both genotypes, the number of immune cells in 
OVA- exposed pups was normalized to the number in PBS controls. *p<O.l; **p<0.05; 
***p<O.Ol. 
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4.4.6 NT4/TrkB signaling is required for OVA-induced AHR. 
We then tested whether increased innervation was functionally linked to ASM thickening 
and AHR using NT4_1_ mice and lNMPPl-treated TrkffA!FA mice, as these mice had lung 
inflammation but no change in ASM innervation after OVA exposure. Quantification of 
ocSMA immune labeling of lung sections showed that OVA exposure increased ocSMA 
density two-fold in the airways of NT4_1_ and lNMPPl-treated TrkffA!FA pups, similar to 
the WT pups (Fig. 4.8 A, B compared to Fig. lC). However, in contrast to WT mice (Fig. 
4.1 G), OVA-exposed NT4_1_ pups exhibited no AHR at P21 or after they reached 
adulthood (Fig. 4.8 C and E). In addition, lNMPPl treatment also diminished AHR in 
OVA-exposed TrkffA!FA pups at P21 (Fig. 4.8 D). These observations suggest that 
increased innervation after early-life allergen exposure affects the ASM phenotype. 
4.4. 7 NT4 is required for ASM basal contractility and OVA-induced hyper-reactive 
phenotype. 
To assess a role ofNT4 signaling in regulating ASM contractility, we compared ASM 
contraction in lung slices from PBS- and OVA-exposed WT and NT4_1_ pups at P21 (179). 
We chose to assay medium-sized airways in which no intrinsic neurons are located (24) 
and therefore, ASM contraction was induced by methacholine free of neural input. All 
lung slices were pre-treated with 30 J.!M isoproterenol, a ~2-adrenergic receptor agonist, 
to completely relax ASM so that potential baseline differences in contraction were 
eliminated. Following methacholine treatment, all airways exhibited a dose-dependent 
reduction of the luminal area, indicative of ASM contraction (Fig. 4.9 A). Control slices 
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Figure 4.8 NT4-activated TrkB signaling is required for airway hyper-reactivity in 
the neonatal asthma model. 
A, B. Representative images of <XSMA-labeled lung sections from PBS- or OVA-exposed 
NT4_1_ pups and lNMPPl-treated TrkffA!FA pups at P21. Arrows point to <XSMA+ ASM. 
*denotes blood vessels also labeled with the <XSMA antibody. Scale bars, 50 llffi. C. 
Airway resistance of P21 WT and NT4_1_ mice that were exposed to PBS or OVA (n=9 for 
each group). D. Airway resistance of WT and 1 NMPP 1-treated TrkeF' AIFA ~ups that were 
exposed to PBS or OVA (WT-PBS, n=12; WT-OVA, n=9; Trkff FA_PBS, n=9; 
TrkffAIFA_OVA, n=l2). E. Airway resistance of adult WT and NT4_1_ mice that were 
previously exposed to PBS and OVA as pups (WT-PBS, n=9; NT4-1--PBS; n=9; WT-
OVA, n=13; NT4-1--0VA, n=l6). Data represent the average of each group from 3 
separate experiments. WT mice analyzed for airway resistance in these sets of studies 
partially overlapped the group of WT mice for studies in Fig. IG. *p<O.l ; **p<0.05; 
***p<O.Ol. 
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from WT pups exhibited little contraction at 10-7 M methacholine and contracted by up to 
50% area at higher doses (Fig. 4.9 A). In comparison, lung slices from OVA-exposed WT 
pups significantly reduced the luminal area by 25% at 10-7 M and maximally reduced the 
area by 80% at 10-5M methacholine (Fig. 4.9 A). These fmdings indicate that early-life 
OVA exposure significantly increased the sensitivity and the magnitude of contraction of 
ASM in response to methacholine in WT mice. Notably, while NT4 deficiency had no 
effect on baseline contraction, NT4_1_ lung slices from both PBS- and OVA-exposed pups 
exhibited greatly reduced methacholine response. The maximal contraction of NT4_1_ lung 
slices from PBS-exposed pups led to only 20% reduction in the airway luminal area, and 
lung slices from OVA-exposed NT4_1_ pups exhibited a similar dose curve to 
methacholine as PBS-exposed WT pups (Fig. 4.9 A). These data further support a role for 
NT4-dependent innervation in controlling the contractile phenotype of ASM. 
We then compared biophysical properties of individual ASM cells isolated from WT and 
NT4-1-1ungs using traction force microscopy. To allow purification of ASM cells by cell 
sorting, we generated an aSMA-GFP;NG2-dsRed double fluorescent mouse. In this 
mouse, dsRed was found to be expressed in pericytes, some immune cells, and vascular 
smooth muscle cells, but not ASM at P21 (Fig. 4.9 B) (45,187). As a result, ASM cells 
can be separated from vascular smooth muscle cells by single GFP positivity (Fig. 4.9 B). 
Dissociated lung cells in suspension were stained for additional markers to allow 
separation of dead cells ( efluor+), endothelial cells (CD31 +), and immune cells (CD45) . 
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Figure 4.9 NT4 is required for OVA-induced increase in ASM contractile 
phenotypes. 
A. Measurement of methacholine-induced ASM contraction using lung slices. All lung 
slices were pre-treated with isoproterenol to diminish differences in baseline contraction. 
A minimum of 26 airways from three mice were analyzed for each condition. B. 
Differential GFP and dsRed expression in aSMA-GFP;NG2-dsRed pups at P21. 
Arrowheads point to GFP+ ASM. * denotes blood vessels that were GFP+ and dsRed+. 
Scale bars, 50 )J.m. C. Contractile moment measurement of individual ASM cells based 
on their contraction map. ASM cells were isolated from aSMA-GFP;NG2-dsRed and 
NT4·1-;aSMA-GFP;NG2-dsRed pups after PBS and OVA exposure at P21. Each dot 
represented the measurement of one single ASM cell and the line represented the average 
within the group. D. Representative contraction maps of a single ASM cell isolated from 
lungs of OVA-exposed WT and NT4_1_ pups. Inserts show the imaged GFP+ ASM cells. 
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Scale bars, 50 !J.m. ***p<O.Ol. 
A stringent sorting algmithm was designed to further exclude possible myofibroblast 
cells with low GFP expression. We bred the NT4_1_ mouse into this double fluorescent 
background so that a pure population of ASM cells ( efluor-CD45-CD31-hrGFP+ dsRed-) 
could be isolated from the lungs of both genotypes. After isolation, ASM cells were 
plated on collagen 1-coated plates that were impregnated with red fluorescent nanobeads. 
Individual ASM cells and nanobeads were live imaged based on their fluorescence. The 
contractile moment was calculated by quantifying the extent of the bead displacement 
before and after cell removal by trypsin (180,181). We found that NT4 deficiency had no 
effect on the basal contractile moment measurement (Fig. 4.9 C). In addition, ASM cells 
isolated from OVA-exposed WT pups at P21 had a greater contractile moment compared 
to WT PBS control cells (Fig. 4.9 C), consistent with an OVA-induced increase in basal 
tone of ASM cells. In contrast, OVA-exposure had no effect on contractile moment of 
NT4_1_ ASM cells (Fig. 4.9 C and D). Collectively, our results indicate that NT4 is 
required for ASM basal contractility and the hyper-reactive phenotype after OVA-
exposure. 
4.5 Discussion 
Our studies show that early-life allergen exposure increases ASM innervation by 
elevating NT4/TrkB signaling, a pathway required for postnatal airway innervation. By 
employing mice with genetic or pharmacologic disruption of this pathway, we found that 
while the NT4/TrkB-dependent signaling is not required for allergen-induced immune 
responses or ASM hyperplasia, it is required for development of acute and sustained 
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airway hyper-reactivity. We further demonstrate that the ASM phenotype during normal 
postnatal growth and after early-life allergen exposure is dependent on NT4 signaling. 
Based on these findings, we propose that increased innervation after early-life allergen 
exposure is functionally linked to persistent alterations in ASM phenotype. In our model 
(Fig. 4.10), NT4 acts as a target-derived signal for ASM innervation by TrkB-expressing 
neurons during postnatal development. In pathological states such as early-life allergen 
exposure, up-regulated NT4/TrkB signaling leads to increased ASM innervation. 
Elevated innervation alters the ASM phenotype, ultimately resulting in persistent anway 
hyper-reactivity (Fig. 4.10 A). Deficiency in NT4/TrkB signaling blocks allergen-induced 
increases in ASM innervation thereby preventing aberrant changes in ASM contractility 
(Fig. 4.10 B). All together, these findings provide a potential explanation for the positive 
correlation between NT4levels and asthma disease severity in children (168). In addition, 
our study may help to explain why children with RSV infection and exposure to 
aeroallergens, ozone, and cigarette smoke exhibit sustained ailway dysfunction into 
adulthood (161, 163). 
We found that NT4 signaling is required for allergen-induced airway hyper-reactivity by 
both in vivo measurement using Flexivent and ex vivo lung slices. In both assays, the 
airways of OVA-exposed NT4_1_ pups exhibit a similar dose response to methacholine as 
PBS-exposed WT pups. However, these two assays had different results with PBS-
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Figure 4.10 A model of how increased ASM innervation after early-life allergen 
exposure leads to persistent airway hyper-reactivity. 
A. Schematic of postnatal lung innervation and early life-allergen induced airway hyper-
reactivity. NT4 is an ASM-derived neurotrophic factor for postnatal ASM innervation by 
TrkB-expressing extrinsic neurons. Early-life allergen exposure leads to ASM 
hyperplasia and elevates NT4-activated TrkB signaling to increase ASM innervation. 
Increased innervation changes ASM phenotype, ultimately resulting in persistent airway 
hyper-reactivity without ASM hyperplasia. B. Without NT4 signaling, ASM innervation 
in postnatal lung is reduced. In addition, although NT4 deficiency has no effect on ASM 
hyperplasia after early-life allergen exposure, it blocks the increases in ASM innervation, 
which in tum prevents changes in ASM reactivity. 
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exposed NT4_1_ pups. The in vivo measurement did not identify any difference in airway 
reactivity between PBS-exposed WT and NT4_1_ pups. In contrast, the ex vivo lung slice 
assay showed that the airway contraction is different between these two genotypes when 
methacholine was applied at high concentrations. The observed discrepancy may be 
explained by differences in bioavailability of methacholine to ASM, neural input, and 
structural components between these two assay systems. Notably, by comparing PBS-
and OVA-exposed NT4_1_ lung slices, we observed the effect of inflammation on airway 
hyper-reactivity independent ofNT4 signaling. This observation further supports our 
conclusion that NT4 signaling is not required for inflammation and suggests a 
physiological role of neural-dependent mechanisms, in conjunction with airway 
inflammation, in ASM contractility. 
This current study in the lung, along with our previous study in the esophagus ( 161,163 ), 
highlights the functional link between innervation and smooth muscle phenotypes. Our 
data suggest that deregulated release of neurotransmitters and neuropeptides from 
innervating nerves during the neonatal period contribute to long-term changes in the 
ASM phenotype; candidate neurotransmitters in this process include acetylcholine and 
substance P, two known activators of ASM reactivity (159,188). 
Our findings differ from previous studies in which early-life exposure to tobacco smoke, 
ozone, and house dust mite allergen did not elicit an overall increase in airway 
innervation. One possibility is that changes in NT expression and airway innervation are 
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dependent on the type of (85) provocative insult and are also developmentally stage-
specific. Supporting this possibility, the ozone-induced increase in substance P-
containing axons is dependent on the postnatal time window of exposure. While early 
postnatal exposure of tobacco smoke increases NGF expression and neuropeptide Y 
levels without affecting overall innervation level in mice (166), perinatal environmental 
tobacco smoke exposure increases substance P-containing axons in the lungs of infant 
primates in association with elevated circulating BDNF levels (167). Impmtantly, other 
studies in primates after ozone and allergen exposure focused on neural changes in the 
airway epithelium (121), a structure that is not abundantly innervated in mice. Of note, 
several of these studies have suggested that increased substance P levels may contribute 
to long-term airway hyper-reactivity (167), which is consistent with our hypothesis. 
In summary, we identified a NT4-activated TrkB signaling mechanism that functionally 
links early life allergen exposure, increased airway innervation, and persistent changes in 
ASM phenotype. This study further underscores a paradigm wherein insults to the 
developing lung can lead to irreversible changes in lung cell phenotype, thereby resulting 
in adult disease. Based on our fmdings, it may be possible to develop treatment strategies 
that prevent the progression from childhood to adult asthma. 
84 
CHAPTER 5: Unpublished Experiments 
5.1 Introduction 
This chapter will cover experiments that are not presented in my papers due to one of the 
following reasons: 
1. The experiment yielded informative but negative results 
2. The experiments were designed to address an important biological question but 
failed because of technical limitations 
3. The experiment lead to a start of a new project and therefore is incomplete in the 
current form 
4. Human studies have lots of variations and it is hard to draw conclusions based on 
small sample size 
5.2 Cockroach allergen 
All of my asthma models use ovalbumin (OVA) as an allergen to prime and stimulate the 
mouse immune system. To test whether my findings from the OVA model are applicable 
to other types of allergen stimulation, I also tested cockroach allergen. Cockroach 
allergen is a relevant human allergen that contains protease activity (189). 
We found that early OVA exposure to mice increased their hyper-reactivity, mucous 
production, BSM thickening, OVA-specific IgE levels, and innervation levels. To make 
sure our findings were not specific to OVA, we repeated the early allergen exposure 
using German cockroach allergen. Mice were given 10 J..Ll cockroach intranasally at P5, 
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PlO, and Pl5 (Fig. 5.1 A). We perfmmed Flexivent analysis on them at P21, and 
harvested them similarly to the OVA-treated mice. Again, we found that cockroach-
treated mice had increased airway hyper-reactivity, mucous production, BSM thickening, 
OVA-specific IgE levels, and NT4 protein levels, and innervation levels (Fig. 5.1). These 
findings showed that the increase in innervation was not specific to our OVA model and 
may be a mechanism of early allergen exposure. 
We were going to run both the OVA and cockroach models in parallel to look into 
asthma persistence and adult acute asthma but decided that it would be too much work 
for a thesis. Therefore, our findings that OVA-treated mice have asthma persistence into 
adulthood and the lack of innervation changes in OVA-induced adult acute asthma 
remain to be validated using other allergens. 
5.3 Mast cells 
My work has largely been focused on the relationship between the nerves and the BSM. 
However, many studies have shown that the immune cells cross-talk with the BSM as 
well as the nerves. I did not have enough time to dive deep into the role of immune cells 
in early allergen exposure, but I did perform a few preliminary experiments on mast cells. 
Studies have shown that mast cells play a role in asthma and that they make and secrete a 
86 
A 
D 
8 PBS CR 
P5 P10 P15 P21 
I I I I 
L_ intranasal cockroach _j FV 
:; 4 P21 
~ 
0 
~ 3 
~2&---~.---~~--~ 
Q) 
'5 
0 
.2 1 • PBS 
+ CR 
m 
0:: 
0oL---~5-----1~5----~25 
Methacholine (mglml) 
E 
Oug/ml 15ug/ml 40ug/ml 
NT41 '·"'' c<f.,c ·•~< .~ 
GAPDHI - - - .. -- ...... ___ ..., I 
c15 P21 
~ 
"' c: ~ . 1 0 
c: 
.Q 
iO 
~.05 
c: 
.!0 
1.0 
F 
:::) 
ci 0.5 ;:. 
z 
PBS CR 
0 15 40 
Cockroach (ug/ml) 
Figure 5.1 Cockroach exposure increases AHR, NT4levels and innervation. 
A. Schematic of cockroach instillation into neonatal WT mice. B. Representative images 
from immunostaining for beta-tubulin III using the TuJl antibody in PBS and CR-treated 
mice. C. Quantification of innervation density. D. Airway resistance in PBS and CR-
treated neonates. E. Western blot analysis for NT4 protein levels in CR treated mice. F. 
Quantification ofNT4 protein levels in densitometry units normalized to GAPDH. Scale 
bar is 100 ~- **p<0.05. 
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number of mediators including histamine, proteases, and neurotrophins. Mast cells in the 
lung are often found in between the epithelium and ASM. Since NT4 is an essential 
neurotrophin in our OVA-induced early allergen model, we wanted to know ifmast cells 
were a source ofNT4. Kruti Patel and Kavon Kaboli plated a mouse mast cell line and 
treated them with PBS controls or IL-16. IL-16 is known to activate mast cells and cause 
them to degranulate. After 48 hours of treatment, we performed western blot analysis on 
the cell supernatant for NT4 and BDNF. We found that at baseline, the cells secreted both 
neurotrophins and that IL-16 treatment induced even more secretion ofNT4 and BDNF 
(Fig. 5.2 A-C). Thus, it seemed likely that mast cells could be a source ofNT4 during 
early allergen exposure. 
Next, Kruti counted the number of mast cells in neonatal mice treated with or without 
OVA using toluidine blue staining. She found that OVA-exposure increased the number 
of mast cells (Fig. 5.2 D). This data showed that mast cells could play a role in early 
allergen exposure. 
To explore the role of mast cells in early allergen exposure, we purchasedKitw-sh mice 
from Jackson labs. These mice have a reduction in their overall numbers of mast cells. 
This also results in a defect in skin pigmentation; they are half black and half white but 
are still on the C57/Bl6 background. We treated these mice with OVA according to our 
neonatal asthma protocol and performed similar analyses when they were P21. We found 
that these mice have a high airway resistance at baseline but do not respond to 
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Figure 5.2 Mast cells secrete neurotrophins in vitro. 
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A. Western blot analysis ofNT4 and BDNF in mast cells supernatant treated with PBS or 
IL-16 for 48 hours. Quantification ofNT4 (B) and BDNF (C) protein levels normalized 
to total protein. D. Number of mast cells per mm2 oflung in vitro in neonatal mice treated 
with or without OVA. 
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Figure 5.3 Kit w-sb neonates may have decreased AHR. 
A. Airway resistance absolute values in WT and KitW-Sh neonates treated with or without 
OVA. B. Airway resistance values normalized to baseline. 
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methacholine doses (Fig. 5.3 A). However, when the airway resistance values are 
normalized to baseline, it seems as if the OVA-treated KitW-Sh mice do not have airway 
hyper-reactivity compared to OVA-treated WT mice at P21 (Fig. 5.3 B). There are some 
concerns however in how to normalize the data or to present the raw data. I also 
quantified their innervation density by immunohistochemical staining of TuJl and 
western blot analysis ofNF. Regardless of OVA treatment, the KitW-Sh mice have lower 
levels of innervation (Fig. 5.4). It seems as if mast cells are implicated in early allergen 
exposure and hyper-innervation. More studies like direct NT4 staining of the mast cells in 
vivo and rescuing the KitW-Sh decrease in innervation by reintroducing mast cells are 
needed to verify this hypothesis. 
5.4 Subtypes of ASM innervation 
It is known that three types of innervation are present in the lung: cholinergic, non-
cholinergic, and sensory. We wanted to know if OVA increased all three types of 
innervation. 
We first started by performing histology on neonatal asthma sections using CGRP 
(calcitonin gene related peptide, marks sensory nerves), YaCht (vesicular acetylcholine 
transferase, marks cholinergic nerves), and TH (tyrosine hydroxylase, marks non-
cholinergic nerves) (Fig. 5.5). Unfortunately, the majority of nerve markers are designed 
for experiments in rats, not mice. Also, while the lung is innervated, there are not a lot of 
axons and neural peptides in the tissue making histology difficult. YaCht and TH had 
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Figure 5.4 Mast cell deficient mice, KitW-SII, have reduced innervation levels 
regardless of OVA treatment. 
A. Representative images of beta tubulin III stained by TuJl antibody in WT and Kit w-sh 
neonates treated with or without OVA .. B. Quantification of innervation density. C. 
Western blot analysis of neurofilament levels in WT and Kitw-sh neonates. D. 
Quantification ofNF protein levels n01malized to GAPDH. Scale bar is 100 J..LM. 
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Figure 5.5 Immunohistochemistry of various neural markers in P21 WT lung 
sections. 
A. CGRP marks the sensory nerves. B. VaChT marks cholinergic nerves. C. TH marks 
non-cholinergic nerves. Scale bar is 100 ~-
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non-specific reactivity in the lung tissue. We did find CGRP positive fibers in the lung. 
CGRP also marks neuroendocrine bodies (NEBs) in the epithelium. We found that while 
WT OVA mice have overall higher levels of innervation (by TuJl staining) CGRP was 
expressed in equal levels compared to PBS controls. However, we found that CGRP was 
increased in the WT OVA persistence mice despite comparable levels of innervation (by 
TuJl staining) compared to PBS controls. This may mean that over time, non-sensory 
afferents were increased in the neonatal asthma mice and were pruned back during 
recovery to reveal a different composition of nerves in the adult lung. 
5.5 ScaleA2 
Since we could not get all of the neural antibodies to work in the mouse lung, we wanted 
to try a different way to visualize the neural network in the lung. Hama et al. (190) 
revealed a solution that would produce clear organs while maintaining fluorescently-
labeled proteins. There were two types of Scale solutions introduced in the paper, A2 and 
U2. U2 has a higher percentage of glycerol (30% glycerol, 4 M urea, 0.1% Triton X-1 00) 
so the transparency is quicker but the cells enlarge. We decided to use the A2 solution 
(10% glycerol, 4 M urea, 0.1% Triton X-100) to maintain the shape ofthe lung. We had 
been able to do whole mount staining and imaging of the embryonic lung with TuJ1 (40) 
but there were too many cells in the postnatal1ung to visualize the staining. With the 
ScaleA2 solution, we could make lungs transparent in mice that had fluorescently labeled 
lung axons. We first tried out the ScaleU2 solution in a P5 SMA-GFP+ lung for seven 
days and imaged it under the GFP fluorescent channel (Fig. 5.6). 
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Figure 5.6 PS SMA-GFP+ lung after treatment with ScaleU2 solution for 7 days. 
Scale bar is 100 ~-
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We were able to visualize the branching aitways. Next, we needed a protein that was 
abundantly and specifically expressed in lung axons. The Blustajn lab was using Chat-
GFP (cholinergic acetyl transferase) mice for their work in brains. We obtained the adult 
lungs from these mice and placed them in the ScaleA2 solution for 3 weeks. We also 
harvested the brains as a control. Once the organs became transparent, we visualized 
them under a GFP microscope. The brains were bright green in areas that were Chat 
positive but the lungs were not green at all. While the ScaleA2 solution preserved the 
integrity of GFP and tumed the lungs transparent, either there was not enough Chat 
protein to visualize the GFP or GFP was not a bright enough fluorophore. 
We also generated a mouse line in an attempt to label all axons in the lung with Tomato 
red, the brightest fluorescent marker currently available. This mouse was generated by 
crossing the Thyl-Cre mouse with a Rosa(trnRed) mouse. Thyl-Cre has been shown to 
be expressed in all neurons in the brain. We harvested the lungs and brains at P21 and put 
them in the scale solution. All of the alveolar cells were bright red proving that this 
method works. Unfortunately, since Thyl is widely expressed in the alveolar cells in the 
lung, the lungs were bright red and we were unable to visualize the axons. We will need 
to identify a Cre line that expresses the Cre recombinase specifically in neurons or 
specific types of nerves in the lung for our studies. Once identified, we can then answer 
more specific questions: how many axons innervate an airway? Does OVA increase axon 
branching or bring in new axons? 
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5.6 Capsaicin with Buxco and Flexivent 
Airway resistance to methacholine (chemical analog to acetylcholine) using Flexivent is 
the gold standard assay in asthma studies. Asthmatic mice have a higher airway 
resistance compared to controls. Other tests of asthma include: BSM thickening, 
increased inflammation, increased lgE, and mucous production. When we first tested our 
OVA-induced neonatal asthma model, we wanted to examine as many assays as we could 
in each mouse. Therefore, after we performed Flexivent analysis at P21, we harvested 
each lobe of the lung for histology, qPCR, and western blot analysis. 
But we wanted more lung physiology. Specifically, we wanted a more direct measure of 
the effect of lung innervation on BSM since methacholine bypasses the nerves and binds 
directly to the muscarinic 3 receptor on the BSM to induce contraction. And since 
Flexivent analysis is an endpoint assay, we looked into Buxco. Buxco is a non-invasive 
measurement of lung physiology. Unanesthetized mice are place in a tube-shaped 
chamber and changes in air resistance are measured as PenH (the pause in between 
breaths). We can deliver increasing doses of aerosolized solutions to the mice and 
measure their PenH response. Since Buxco is non-invasive, we decided to run the mice 
on Buxco at P20 and Flexivent at P21 . 
We tried two chemicals that work on the nerves, capsaicin and thromboxane. Capsaicin 
binds to the TRPV receptor on the sensory nerves while thromboxane stimulates the 
cholinergic nerves. First, we tried delivering thromboxane to untreated adult WT mice. 
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They responded to the thromboxane with increasing PenH (data not shown). However, 
thromboxane is very expensive, and it would not be feasible to carry out these 
experiments on our other mice. We then tried Buxco capsaicin experiments on untreated 
adult mice. Increasing doses of capsaicin increased PenH levels in the WT mice 
compared to the NT4·1· adults (Fig. 5.7 A). However, the Buxco chambers are not 
designed for small mice, and the neonatal numbers in the capsaicin experiments were 
varied (Fig. 5.7 B). The Buxco machine is also extremely sensitive. Walking by or 
talking during the run can alter the numbers. Also, in the asthma research community, 
Buxco data is met with skepticism because it is non-invasive and very sensitive. 
Therefore, after two rounds of neonatal mice, we decided to stop these experiments. 
Later, we found that another unfortunate side effect was that high doses of inhaled 
capsaicin killed off the lung sensory nerves. So we had to repeat the Flexivent and 
histology experiments with new mouse litters. Later, we did revisit the capsaicin 
experiment but delivered aerosolized capsaicin to the mice while they were on the 
Flexivent. The neonatal mice treated with OVA had AHR compared to PBS controls 
(Fig. 5.7 C). These results show that the neonatal mice may have increased sensory 
nerves and/or TRPV receptors with OVA treatment. We will need to repeat this 
experiment in the WT persistence mice as well as the NT4·I· neonates treated with OVA. 
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Figure 5. 7 PenH and airway reactivity increase with capsaicin treatment. 
A. PenH levels from WT and NT4_1_ adult mice in response to capsaicin. B. PenH levels 
from WT and NT4_1_ neonates treated with or without OVA in response to capsaicin. C. 
Airway resistance levels normalized to baseline in WT neonates treated with or without 
OVA in response to capsaicin. 
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5.7 Vagal stimulation and vagotomy 
Since the Buxco experiments were inconclusive, we still could not answer: what is the 
direct effect of innervation on BSM? There were a few studies in rabbits and guinea pigs 
that addressed this by electrical stimulation of the vagus nerves. There are two vagus 
nerves that run along each side the trachea and innervate the lung along with other 
organs. I traveled to Oregon Health and Science University to learn how to stimulate the 
vagus nerve in guinea pigs from Allison Fryer's lab (51) . The procedure is long and 
tedious. Briefly, guinea pigs are anesthetized, the jugular veins are cannulated to deliver 
more anesthesia, the trachea is cannulated to measure airway resistance, the vagus nerves 
are carefully dissected and placed on electrodes, the fur around the neck is sown together 
to make a well to hold mineral oil for the sensitive nerve endings, the nerves are warmed 
up with electrical pulses, and then gradually increased electrical pulses are delivered to 
the vagus nerves and airway resistance is measured. This is difficult to do in guinea pigs. 
Guinea pigs are 1 OOx the weight of a neonatal mouse. There has only been one lab that 
has successfully electrically stimulated the vagus nerves in adult mice. I adopted the 
procedure for mice by not including the jugular vein cannulation. We made our own 
electrodes and a collar for the mouse to hold mineral oil. I tried this procedure in adult 
and neonatal mice but could not get the stimulation to alter the airway resistance. 
Next, we tried vagotomies. We had shown previously that WT OVA-treated mice have a 
higher airway resistance at baseline. So we took a measurement of airway resistance at 
baseline, cut both vagus nerves, and measured airway resistance again after vagotomy. If 
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the airway resistance decreased, that would tell us that the nerves are playing a role in 
maintaining baseline airway hyper-reactivity. In adult mice, the airway reactivity at 
baseline pre and post vagotomy was unchanged (Fig. 5.8 A). However, in the adult mice 
with the vagotomy, they had lower airway reactivity in response to McH (Fig. 5.8 B). 
Unfortunately, when we repeated the experiment in the neonatal mice, they did not 
display any changes. It was difficult to tell if the lack of change was due to the small size 
of the neonatal mouse or if there are no changes after vagotomy. Of note, there is a 
feedback loop with acetylcholine release from the nerves. The studies that show guinea 
pig airway resistance values to methacholine also perfmm vagotomies before 
measurement to ensure there is no additional release of acetylcholine onto the BSM, 
falsely increasing the dose response. However, when acetylcholine is released from the 
nerves, it binds to the M3 receptors on the BSM and it also binds to the M2 receptors on 
the axons to inhibit further acetylcholine release. When we deliver methacholine to the 
mice, it is likely that it also binds the M2 receptors to inhibit acetylcholine contributions 
from the nerves. 
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Figure 5.8 AHR decreases with vagotomy in adult WT mice. 
A. Airway resistance values at baseline in WT adult mice pre and post vagotomy. B. 
Airway resistance values normalized to baseline in WT adult mice with or without 
vagotomy in response to McH. 
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5.8 Electrical stimulation on lung slices 
Since the vagal stimulation did not work, we still wanted to do a direct assay to see the 
effect of the nerves on the lung. We collaborated with Michael Sanderson who works on 
lung slices ( 179,191 ). Mice were put down by anesthesia and cannulated through the 
trachea. We instilled 3-4 mL 1% low melting agarose through the trachea to inflate the 
lungs followed by 0.5 mL air. The trachea was tied off and the inflated lungs were 
dissected and placed in3% agarose. The lungs were sliced to 0.5 mrn on VF-300 
microtome (Precisionary Instruments). 
When the slices are incubated at 37°C, the agarose inside of the lung melts. We added 
PBS to the lung slices and tried to stimulate them by putting both electrodes in the PBS 
and adding electrical pulses. We could not see the airways contract. We will need to 
improve this method for direct nerve stimulation. 
5.9 Dihydroxyflavone (DHF) 
Since we found that OVA-treatment in WT neonatal mice increases airway reactivity and 
BSM innervation through TrkB signaling, we wanted to know if increased innervation 
through a TrkB agonist was sufficient to increase airway reactivity. To induce airway 
hyper-innervation, Rebecca Achey treated neonatal mice with dihydroxyflavone (DHF), a 
TrkB agonist, intranasally from P10-P16 and examined their innervation levels at P21 via 
western blot analysis of neurofilament and histology by TuJ1 . She found that DHF 
increased neurofilament levels via western blot analaysis and beta-tubulin levels via 
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histology compared to vehicle controls (Fig. 5.9). She also found that DHF increased 
phospho-TrkB levels without affecting mucin production (Fig. 5.10 A, B, D). She also 
looked to see if AHR was affected by DHF treatment. She found that neonates treated 
with DHF have AHR compared to vehicle controls (Fig. 5.10 C). But then numbers are 
low and the experiment will need to be repeated. 
However, when we treated neonates with DHF and OVA to see ifwe would have a 
bigger increase in innervation, phospho-TrkB levels decrease compared to DHF -treated 
mice (Fig. 5.10 A, B). Since lung innervation peaks at P14, axons may be pruned if they 
do not reach their target. DHF treatment alone may inhibit axon pruning by increasing 
TrkB signaling to axons already present in the lungs. But with OVA treatment, it is likely 
that new axons are being recruited into the lung. But if we deliver DHF during this 
process, the chemical gradient would not have a chance to be set up and the new axons 
may not have a chance to get inside the lung. 
A better experiment would be to create a mouse that overexpresses NT4 only in the lung 
BSM. This way, the chemical gradient can be set up to attract axons to synapse with the 
BSM. This more naturally mimics the true biology of lung innervation. 
5.10 K252A 
Since we showed that NT4 is an essential neurotrophin for postnatal innervation, my 
work largely focuses on the role ofNT4 in early allergen exposure using the NT4_1_ 
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Figure 5.9 DHF treatment increases innervation in neonatal mice. 
A. Western blot analysis of neurofilament levels in mice treated with DHF or DMSO 
vehicle control. B. NF densitometry normalized to GAPDH. C. TuJl staining in mice 
treated with DHF or DMSO. 
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Figure 5.10 DHF treatment increases phospho-TrkB levels and AHR. 
25 
A. Western blot analysis of phospho-TrkB levels in mice treated with DHF alone, 
OVA +DHF, or DMSO control. B. Densitometry of phospho-TrkB levels normalized to 
GAPDH. C. Airway reactivity in response to McH. D. Mucin staining. 
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mouse. However, BDNF could be compensating for the loss ofNT4 so I used the 
TrkffAIFA mouse to show that airway reactivity is decreased in these mice treated with 
lNMPPl and OVA. Again, there could also be compensation from the other 
neurotrophins like NGF and/or NT3. NGF has been linked with asthma in many studies. 
NGF and NT3 signal through TrkA and TrkC respectively. To address this, I treated mice 
with a pan-Trk inhibitor, K252A. K252A inhibits phosphorylation of all Trk receptors. 
Neonatal mice were treated with 200 nM K252A intratracheally at P5, PlO, P18, P19, and 
P20. They were sacrificed at P21 similarly to the other neonatal asthma experiments. The 
mice treated with K252A had a decrease in TuJl innervation and airway reactivity 
compared to WT PBS mice without affecting SMA levels (Fig. 5.11). This result is 
consistent with our fmding that NT4ffrkB signaling is required for postnatal ASM 
innervation. Future studies will test whether K252A blocks OVA-induced hyper-
innervation of the lung. If so, it may provide a foundation for development of new drugs 
for asthma treatment. 
5.11 URECA 
Ultimately, we wanted to connect our findings in our mouse models to humans. Since we 
found that NT4 is essential for airway hyper-reactivity in early allergen exposure, we 
wanted to see iflevels ofNT4 were increased in the bronchial lavage fluid of asthmatic 
children. The Urban Environmental and Childhood Asthma (URECA) study follows a 
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Figure 5.11 K252A treatment decreases innervation and airway reactivity without 
affecting aSMA levels. 
A. TuJl immunohistochemistry of mice treated with or without K252A. B. Quantification 
of TuJl staining. C. Airway reactivity in response to McH. D. aSMA 
immunohistochemistry. E. Quantification of aSMA staining. 
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birth cohort of children from five major U.S. cities (192). They collected cord blood and 
are now collecting bronchial lavage fluid from this cohmi every two years through age 7. 
We were fortunate enough to obtain 100 cord blood samples and 100 bronchial lavage 
fluid samples from 3 year olds for an initial study. Half of these children had low IgE 
levels and half of them had high IgE levels. We measured the amount of BDNF, N GF, 
NT3, and NT4 in these samples via ELISA. The study is ongoing and double blinded, so 
our results were analyzed at a study center in Chapel Hill, NC. There were only five 
samples that had really high levels ofNT4 while the rest were undetectable with our 
ELISA kit. However, we found that BDNF in the 3-year old bronchial lavage fluid 
positively conelated with wheeze and the asthma predictor index (API) (Table 5.1 ). 
Asthma is not clinically diagnosed until age 5 but studies have shown that wheeze 
conelates with asthma. The API, created since asthma is not diagnosed until age 5, is a 
spreadsheet of various factors that determines the likelihood of a 3 year old to develop 
asthma later in life. 
Therefore, we obtained 200 bronchial lavage fluid 3-year old samples from the rest ofthe 
cohort to increase our N number. Again, we examined the BDNF levels by ELISA. This 
time, BDNF was no longer conelated to wheeze and the asthma predictor index (Table 
5.2). It is possible that since the first 100 samples were already sorted by high and low 
IgE levels, that BDNF could be a marker of severe asthma. But we will have to wait until 
samples are collected at a later age in this cohort. 
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Cord blood BDNF 
(total n=98) 
Age 3 
BDNF 
(total n= I 00) 
Recurrent wheeze (n=49) 
Modified API (n= 14) 
Eczema (n= 13) 
Allergic to anything tested (n=48) 
Allergic to aeroallergens (n=43) 
Allergic to food (n=29) 
__.. Recurrent wheeze (n=50) 
__.. Modified API (n= I 5) 
Eczema (n= 13) 
Allergic to anything tested (n=50) 
Allergic to aeroallergens (n=45) 
Allergic to food (n=30) 
Outcomes at age 3 Mean BDNF at age 3 
Non-wheezers 
Recurrent wheezers 
No eczema 
Eczema 
913.73 
__.. 1291.27 
Mean BDNF in cord blood 
600.53 
350.39 
0.43 (0.18-1.00) 
0.26 (0.03-1.97) 
0.13 (0.0 1-1.24) 
1.0 I (0.53-1.92) 
0.98 (0.47-2.08) 
0.67 (0.23-1.95) 
3.1 I ( 1.32-7.32) 
2.82 (0.49-16.24) 
0.99 (0.16-6.13) 
1.5 I (0.82-2.80) 
1.49 (0.74-1.98) 
1.80 (0.63-5.1 5) 
P-value from above 
0.01 
0.08 
Table 5.1 BDNF positively correlates with recurrent wheeze and modified API in 3-
year old blood serum in children with high IgE serum levels. 
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Cord blood 
BDNF 
(total n=98) 
Age 3 
BDNF 
(total n=361) 
Recurrent wheeze (n=49) 
Modified API (n=14) 
Recurrent wheeze (n=128) 
Modified API (n=48) 
0.43 (0.18-1.00) 
0.26 (0.03-1.97) 
0.88 (0.55-1.42) 
1.72 (0.67-4.39) 
Table 5.2 BDNF does not correlate with recurrent wheeze or the modified API in 3-
year old blood serum when samples were not selected for high-IgE levels. 
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5.12 Fatal asthma patient samples 
We were also able to obtain histological samples of patients who died from asthma and a 
control group. Again, we wanted to connect our fmdings in our mouse models to human 
patients. We wanted to see if the patients who died from asthma had increased lung 
innervation. We stained the lung sections with fluorescently labeled TuJl, TuJ1-Cy3, and 
SMA-FITC. We first tried to tile the images to quantify the entire airway. But for 
practicality we could only tile at 4x magnification. At 4x magnification, the TuJ1 was not 
clearly defined so we could not do the quantification (Fig. 5.12). We needed a resolution 
of at least 20x to see the axons but the entire airway could not fit in that magnification. 
We centered the airways on the microscope and took four images at north, south, east, 
and west of the center for each airway. Then we opened the images in ImageJ and 
thresholded the TuJl-positive area divided by the length ofthe airway (Fig. 5.13). 
Unfortunately, it was hard to correlate increased innervation with fatal asthma because 
we had low N numbers. With preliminary data, the fatal asthmatics may have increased 
innervation levels (Fig. 5.14). But our study focuses on early allergen exposure and 
increased innervation not fatal versus non-fatal asthma. We had some patient data on the 
samples, and wanted to see if fatal asthmatic patients under the age of 10 had increased 
innervation compared to controls but again, this further decreased our N numbers. 
Therefore, unless more samples are obtained, it is hard to draw conclusions. 
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Figure 5.12 Human airway stained with TuJl, SMA, and Dapi. 
113 
1. Image 4 quadrants at 20x 
2. Threshold SMA 
3. Threshold TuJ1+ area within SMA 
4. Divide TuJ1 area by SMA area 
SMA20x TuJ1 20x 
Figure 5.13 Example of TuJl quantification in human airway sections. 
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Figure 5.14 Fatal asthmatic humans may have increased innervation levels. 
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CHAPTER 6: Neural regulation of mucous production 
6.1 Introduction 
Mucus secretion in the lung plays an important role in host defense. But hyper-secretion 
of mucus can be harmful, and in some cases lethal. Triggered by allergens, inhaled 
toxins, and chronic infections, mucus hyper-secretion causes impaired mucociliary 
clearance leading to infection and airway obstruction. Mucus hyper-secretion and goblet 
cell metaplasia contribute significantly to the pathogenesis of asthma, chronic obstructive 
pulmonary disease (COPD), and cystic fibrosis. 
Mucus is comprised of water, lipids, proteins, and large, complex glycoproteins called 
mucins. More than 20 mucin genes have been found in the lung, nose, salivary glands, GI 
tract, and uterus (193). Although 12 mucin genes are expressed in the lung, MUC5AC 
and MUC5B are predominant (194,195). MUC5B is produced in the submucosal glands 
while MUC5AC appears to be synthesized in the airway epithelium by goblet cells. 
Goblet cells have many mucin granules that make up more than 75% of their cytoplasm 
(196). While healthy individuals have less than 5% goblet cells in their airway 
epithelium, fatal asthmatics have 20-25% goblet cells (197). Mucus plugging may be the 
cause of death in fatal asthma. Current treatment focuses on reducing inflammation and 
breaking up mucus but not hyper-secretion prevention. Thus, it is crucial to fully 
understand the mechanism of mucus hyper-secretion. 
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In mice, the lung epithelium is comprised of ciliated and nonciliated cells including 
Clara, serous, basal, neuroepithlial (NEB), and goblet cells. Normally, there are few 
goblet cells present in the lung. During TH2 inflammation, Clara cells transdifferentiate 
into goblet cells and then synthesize and secrete mucin. Studies have confirmed that this 
occurs through metaplasia rather than hyperplasia. Many mediators have been shown to 
stimulate mucin secretion including cholinergic agonists, cytokines, neuropeptides, A TP 
and UTP, bacterial products, neutrophil elastase, and inhaled pollutants (198). When 
these mediators dissipate, goblet cells undergo apoptosis and are replaced by the normal 
epithelium, mostly Clara and ciliated cells. However, in many airway diseases, these 
stimulants persist leading to mucus hyper-secretion and airway obstruction (198). 
In our model of early allergen exposure, we found that NT4 plays a key role in lung 
innervation and AHR. Recently, we discovered that genetic ablation ofNT4 and 
pharmaceutical blockade of TrkB signaling also inhibits mucus production despite 
allergen challenge. We speculate that a neural mechanism is at play based on our fmding 
that NT4 receptors, TrkB and P75, are only expressed by innervating axons. A previous 
study showed that GABA, a neurotransmitter, is involved in mucus production since 
GABA antagonists in WT allergen-treated mice blocked mucin production (199). We 
thus hypothesized that the GABA pathway is altered in the NT4_1_ pups, leading to 
reduced mucin production after allergen exposure. 
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This chapter provides several preliminary findings that suppmt this hypothesis. First, we 
characterized the expression of two GABA synthetic enzymes, glutamate decarboxylase 
1 & 2 (GADl and GAD2), in the postnatal lung. We found that only GADl is expressed 
selectively by NEBs that are innervated by an NT4-dependent mechanism (48). 
Secondly, while NT4 deficiency has no effect on NEB formation, the expression of 
QADI by NEBs is reduced in NT4·1-lungs as compared to WT controls. Thirdly, in 
contrast to WT lungs in which OVA exposure increased the abundance of epithelial 
CCI 0+ secretory cells, NT4_1_ pups show no such change. These fmdings suggest that 
upstream neural signals regulate GABA release to control goblet cell differentiation. 
Future work is required to establish the mechanistic link between NT4 and mucin in 
allergen-exposed airways. 
Understanding how NT4 plays a role in mucus production is important for identification 
of novel mucus mechanisms. Insights gained from these studies will provide a foundation 
for discovery of new drugs that target mucus production. 
6.2 Methods 
6.2.1 PAS stain and quantification 
For mucin staining, sections were processed with the Periodic acid-schiff (PAS) staining 
system (395B-1KT Sigma Aldrich) following the manufacturer's protocol. Briefly, 5 1-1M 
paraffin lung sections were hydrated in a series of ethanol. Slides were incubated with 
395-1 for 5 minutes, 395-2 for 15 minutes, and Gil13 GHS-3 for 90 seconds. The sections 
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were dehydrated in a series of ethanol followed by xylene and coverslipped with oil and 
nail polish. Mucin positive areas are pink, the rest of the cells are stained purple. 
Medium-sized airways were imaged with 40x bright field microscopy (Zeiss Axioskop 
40). A minimum of five airways from three lung sections in three different mice were 
imaged. For quantification, we used an arbitrary histological score of 1-6 ( 1: no mucin in 
the airway, 6: mucin fully lines the airway in multiple layers). Each airway is scored and 
then all of the scores are added together. 
6.2.2 IL-13 ELISA 
Bronchoalveolar lavage fluid (BALF) was collected from pups after physiological 
measurement on P21. 0.5 mL cold PBS was flushed into the lungs through the cannulated 
trachea, incubated for 30 seconds, and withdrawn. BALF was centrifuged at 1600 RPM 
for 10 minutes. Supernatant was removed and stored at -80°C until use. Samples were 
diluted 1:5 in extraction solution before use. IL-13 levels were assayed using an ELISA 
kit (Life Technologies, KMC2221) following manufacturer's protocol. 
6. 2.3 Immunohistochemistry 
The left lung lobes were harvested, fixed, and embedded in paraffin. Serial sagittal 
sections (5 ~-tm) in the middle of the lobe were collected. Four sections were treated with 
xylene to remove paraffm and rehydrated in ethanol followed by PBS washes. Sections 
were blocked with 2% BSA for one hour and probed for CCSP anti goat (Santa Cruz) 
1:1000. Secondary antibodies were donkey anti goat 488. For MUC5AC, sections were 
blocked with MOM block and probed for MUC5AC anti mouse (Abeam) 1 :500. 
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Secondary antibodies were goat anti mouse 546. Medium-sized airways were imaged 
with 40x bright field microscopy (Zeiss Axioskop 40). 
6.2.4 NEB quantification 
The right apical lobe of the lung was collected and fixed in 4% paraformaldehyde in PBS 
at 4°C ovemight. After cryoprotection in 30% sucrose in PBS, 50 !-liD sections were 
collected along the rostral-caudal axis of the lobe. Four sections, 1 mm apart, were 
imrnunostained using a previously described protocol ( 40) and mounted with 
Fluoromount-0 (eBioscience). Primary antibodies included biotinylated mouse anti-
neural class III f3-tubulin (TuJl, 1:200, R&D, BAM1195) and mouse anti-CORP (1:1000, 
Sigma C8198). Antigen-antibody complexes were detected by fluorescence. After 
staining, sections were imaged using a Zeiss Axiovert 1OOM LSM 510 equipped with an 
Argon and 2 HeNe lasers (Thomwood, NY). Compressed z-stack confocal images were 
presented and quantified. For NEB quantification, CORP-positive cells or clusters in the 
epithelium were counted per imaged airway. Medium sized airways were imaged and 
quantified per slide for a minimum of 25 airways per mouse. The total number of NEBs 
was divided by the number of airways imaged per mouse. These numbers were then 
averaged per mouse and for each treatment. For NEB innervation quantification, CGRP 
and TuJI images were merged. Each CORP-positive cell or cluster was counted as 
innervated if it was also TuJl positive. The total number of innervated NEBs was divided 
by the total number ofNEBs/airway. 
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6.2.5 Gadl-EGFP mice 
The transgenic Gadl-EGFP mice (stock number: 007677, Jackson Laboratories) express 
a green fluorescent protein (EGFP) under the control of GADJ promoter sequences. To 
analyze GAD 1 expression in postnatal lungs, pups were sacrificed at PO, 7, 15, 18 and 
P21. Lungs and brains (as a positive control) were fixed in 4% paraformaldehyde 
overnight, washed in PBS, c1yoprotected in 20% sucrose ovemight, and embedded in 
OCT and frozen on dry ice. The brain and left lobe was cut into 8 !lM frozen sections and 
imaged in the FITC channel on the Zeiss Axioskop 40. To make sure that the GFP 
positive cells were in the NEBs, sections were stained with CGRP anti rabbit 1:1000 
ovemight with secondary antibody goat anti rabbit 546 1:300 and detected by 
fluorescence. Images were merged in ImageJ. Since there was some background 
fluorescence in the sections under the FITC channel, we wanted to stain the sections with 
the GFP antibody using DAB. Sections were stained for GFP anti rabbit 1:100 with 
secondary antibody ofbiotinylated goat anti rabbit 1:250, and detected by DAB. Gad]-
EGFP+ brains were used as a positive control. Gadl-EGFr lungs were used as a 
negative control. 
6 2 6 G d'"~CreERT21+ . . . a ~ mzce 
To identify GAD2-expressing cells in the lung, a knock-in Gad2creERT21+ mouse line 
(stock number: 010702, Jackson Laboratories) was crossed into the Rosa(lacZ) 
background. After tamoxifen administration to Gad2CreERT2/+;Rosa(lacZ) mice, the Cre 
recombinase-activated beta-galactosidase expression was detected by X-gal staining. 
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Three doses of TAM (0.5 mg per dose) was given to the Gad2CreERT2!+;Rosa(lacZ) pups at 
PlO, P14, and P18. Pups were subjected to OVA sensitization and challenges. All pups 
were sacrificed at P21. Lungs were fixed with 1% PF A prior to X -gal staining. 
6.2. 7 GABA ELISA 
GABA levels were assayed in BALF using a GABA ELISA kit according to the 
manufacturer's protocol from Antibodies Online (ABIN1115040). GABA levels were 
also assayed in BALF using a GABA ELISA kit according to the manufacturer's protocol 
from Sigma Aldrich (A031 0-.2ML ). 
6.2.8 Muscimol 
Doses were based on a study that showed intratracheal delivery of 68 pM/5 ~1 into the 
mouse inhibits biting and scratching from excitatory amino acids. Muscimol was stored 
at 20°C in 1 nM concentrations in 286 pM HCL Four WT mice were given 20 ~1 of 
muscimol i.t. at either 100 pM, 250 pM, 500 pM, or 1 nM concentrations ofmuscimol at 
P18, 19, and 20. One WT mouse was given 20 ~1 of286 pM HCl as vehicle control at 
P18-20. All mice were sacrificed at P21. Lungs were fixed, paraffin embedded, and 
stained for PAS as above. 
6.2.9 CGRP slot blot 
BALF was diluted in PBS and used 100 ~1 pure, 1:2, 1:5, and 1:10. BALF proteins were 
transferred to a nitrocellulose membrane on the BioRad Dot Blot system. 100 ~1 of each 
sample was loaded, vacuumed, and washed with PBS + 0.1% Tween. Total protein was 
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stained with ponceau and imaged for nmmalization. Membrane was blocked with 5% 
milk and probed for CGRP anti Rabbit 1: 1000 overnight 4 °C. Membrane was treated with 
ECL and exposed on film. CGRP densitometry was normalized to total protein. 
6.2.10 Quantitative real-time PCR 
Left basal lung lobes and brain were collected and homogenized for total RNA isolation 
using the RNeasy Mini Kit (Qiagen). Total RNA (1 !-Lg) was reverse transcribed using 
SuperScript III First-Strand Synthesis SuperMix (Invitrogen). qPCR was perfmmed using 
the Power SYBR Green PCR Master Mix (Applied Biosystems) on a StepOnePlus Real-
Time PCR System (Applied Biosystems). The relative level ofmRNA expression was 
calculated by normalizing to the housekeeping gene, 18S, mRNA using ~Ct (cycle 
threshold difference) . 
6.3 Results 
6.3.1 Mucin 
Since mucin production in the airways is a clinical hallmark of asthma, we looked for 
mucin production using PAS staining to validate our OVA neonatal asthma model. The 
WT neonatal mouse lungs do not produce mucin at baseline, but when treated with OVA, 
have large amounts of mucin in their airways (Fig. 6.1 ). As we were validating OVA-
exposure in the NT4_1_ mouse, we found that they had similar levels of inflammation and 
SMA thickening but decreased AHR and almost no mucin (Fig. 6.1 ). We found the same 
phenotype in the TrkffAIFAmice treated with OVA and 1NMPP1 (Fig. 6.1). The decrease 
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in AHR confirmed our hypothesis that the nerves play a role in breathing and asthma. 
However, we were surprised by the mucin phenotype because lung innervation largely 
targets the ASM and mucin is produced by goblet cells in the epithelium. 
Another target oflung innervation is neuroendocrine bodies (NEBs). NEBs are widely 
distributed in the lung and are found solitary or in clusters in the lung epithelium. While 
their exact functions are unknown, studies suggest they may play a role in oxygen 
sensing (200) and in regeneration of pulmonary epithelium (44). They produce amine 
( 5HT) and a variety of neuropeptides (bombesin in humans and CGRP in rodents) (20 1 ). 
Yabumoto et al. (202) show that NEBs also synthesize and secrete GABA. Although 
GABA is largely an inhibitory neurotransmitter in the mammalian brain, GABA also 
plays an excitatory role in the lung regulating mucin production (199). 
Thus, we hypothesized that nerves control goblet cell metaplasia and mucous production 
by stimulating the NEBs to release GABA onto Clara cells for transdifferentiation. If this 
were true, then the NT4_1_ mice would have a defect/defects somewhere along this 
pathway. 
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Figure 6.1 OVA treated neonates with reduced innervation have reduced mucin. 
Scale bar is 100 J..LM. 
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6.3.2 NEBs 
First, we looked at the normal distribution ofNEBs in the postnatal lung. We did a time 
course in WT mice at PO, 7, 14, and 21. Kelsi Radzikinas stained thick frozen lung 
sections with CGRP, a marker ofNEBs, and imaged them with confocal microscopy. She 
found that the number ofNEBs per mouse lung peaked around P14 (Fig. 6.2) similar to 
the peak in innervation (Fig. 4.4 D). Next, Rebecca Achey looked to see if the NEB 
number or number of innervated NEBs was affected by OVA treatment or absence of 
NT4. For NEB numbers, she looked for number of CGRP positive cells in the airways. 
For innervated NEBs, she looked for CGRP positive cells that co-localized with TuJ1 . In 
WT or NT4_1_ neonates treated with or without OVA, there was no change in number of 
NEBs (Fig. 6.3). This meant that the NT4 phenotype was not due to a change in NEB 
number. Since the NT4_1_ had a decrease in ASM innervation, we would have expected to 
see a decrease in NEB innervation ifNT4 played a role in NEB innervation. However, 
there was no significant change in total innervation ofNEBs in the WT or NT4_1_ neonates 
(Fig. 6.3). We used a pan-neuronal marker to assess innervation changes. A recent study 
has shown that NT4_1_ mouse lungs have purinergic nerve defects (P2X2+ P2X3+ axons) 
(48). So we will need to look more specifically at loss ofpurinergic nerves in the NEBs. 
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Figure 6.2 The number of NEBs in the postnatal lung peak at P14. 
A. Representative image ofWT lung fluorescently stained with CGRP, TuJl, and DAPI. 
Arrow marks NEB. Scale bar is 100 11M. B. Timecourse for NEB quantification. 
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Figure 6.3 The number of NEBs are not affected by OVA treatment or absence of 
NT4. 
A. NEB quantification in WT and NT4_1_ neonates. B. Innervated NEB quantification. 
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6.3.3 IL-13 
To look into the developmental defect in the NT4_1_ neonate, we next looked upstream of 
mucin production. Many studies have shown that IL-13 alone induces mucin production 
since the IL-13_1_ mouse is not capable of producing mucin. But in the OVA-treated NT4_1_ 
neonates, there are no differences in IL-13 production in the BALF compared to OVA-
treated WT neonates assayed by ELISA (Fig. 6.4). This meant that the mucin defect was 
either downstream ofiL-13 or independent ofiL-13. 
6.3.4 GABA 
Goblet cell metaplasia from Clara cells seems to be a two-hit system. First, EGF signals 
through EGFR to block apoptosis and promote cell survival. Second, IL-13 signals 
through the IL-13 receptor to decrease FoxA2 (Clara cell marker) and increase SPDEF 
and the GABA receptor ( 198). GABA is synthesized by the GAD enzyme. Studies have 
shown that both GAD and GABAR are increased in human asthmatic epithelial cells after 
allergen challenge. Xiang et al. (199) show that GABAR inhibitors suppress goblet cell 
metaplasia and mucous production in WT antigen-challenged mice. Since GABA is a 
neurotransmitter, is located downstream ofiL-13 signaling, and implicated in mucous 
production, we found it to be a likely candidate in the NT4_1_ mucin phenotype. First, we 
wanted to know where GAD was expressed in the lung normally. There are two GADs, 1 
and 2. Using a P15 GAD1-EGFP+ mouse, lung sections were stained with CGRP (NEB 
marker), also imaged in the FITC channel. We found that GADl is only expressed in the 
NEBs (Fig. 6.5). We also used a GAD2creERT2/+;Rosa(lacZ) mouse to look at the 
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Figure 6.4 OVA treated NT41- neonates have similar levels of IL-13 compared to 
OVA-treated WT neonates. 
IL-13 levels in BALF of WT and NT4_1_ assayed by ELISA. 
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Figure 6.5 GADl is only expressed in the NEBs postnatally. 
P15 Gadl-EGFP+ brain slice visualized in the FITC channel. Gadl-EGFP+ lung slice 
stained with CGRP and visuzalized in the FITC channel. Gadl-EGFF brain and lung 
used as a negative control. Scale bar is 100 J.!M. 
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expression ofGAD2 in the lung. Postnatal labeling by tamoxifen at PIO, Pl4, and P18 in 
PBS and OVA-exposed mice showed no GAD2 expression in the lung (data not shown). 
We concluded that GADl is solely expressed in the postnatal NEBs. Next, we wanted to 
know ifMUC5AC and GAD levels were altered in the NT4·1-neonates. We performed 
qPCR for MUC5AC and GAD expression on WT and NT4_1_ neonatal lungs treated with or 
without OVA. We found that MUC5AC mRNA increased with OVA treatment in the WT 
neonates but not in the NT4_1_ (Fig. 6.6 A). This is consistent with the increased mucin 
staining in the WT OVA neonates and no positive mucin staining in the NT4_1_ (Fig. 6.1 ). 
Notably, we found that GAD expression increased in the WT OVA neonates but not in 
the NT4_1_ OVA neonates (Fig. 6.6 B). This shows that NT4 is somehow affecting GAD 
levels in the NEBs. One explanation is that NT4-dependent purinergic nerves release a 
neurotransmitter that up-regulates GAD expression in the NEBs. In the absence ofNT4, 
the NEBs would then make and secrete low levels of GABA since they have a decrease 
in the GAD enzyme. 
Since there was a decrease in GAD expression, we next wanted to see if there was a 
decrease in GABA levels. As GABA has a low mass, we ran a GABA ELISA on BALF 
from WT and NT4_1_ neonates treated with or without OVA. Unfortunately, the ELISA kit 
was not sensitive enough to detect a difference in GABA levels. The standards did not 
even work. Rebecca tried a different ELISA kit and used murine urine (should have 
around 4000 pg/ml GABA) and pure GABA as positive controls. 
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Figure 6.6 MUCSAC mRNA increased in WT OVA lungs while GAD mRNA 
decreased in NT41-Iungs despite OVA treatment. 
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A. MUC5AC mRNA quantification normalized to 18S mRNA. B. Gad67 mRNA 
quantification normalized to 18S mRNA. 
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Figure 6. 7 GABA levels in BALF assayed by ELISA did not work. 
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Murine 
Urine 
The standard curve looked good, but there was no GABA detected in any of the samples, 
including the positive controls (Fig. 6. 7). 
Since we were unable to detect GABA levels directly, we wanted to see if the NEBs were 
activated by measuring proteins that the NEBs normally secrete. NEBs synthesize a 
number of proteins including bombesin and CGRP. We measured CGRP levels in the 
BALF by slot blot analysis. BALF was diluted in PBS. CGRP levels were normalized to 
the total protein ponceau stain. In the WT neonates, there was a slight decrease in CGRP 
levels with OVA treatment (Fig. 6.8). In the NT4_1_ neonates, the CGRP levels almost 
doubled compared to WT but remained unchanged despite OVA treatment (Fig. 6.8). We 
also measured the CGRP axon density in the airways by staining thick frozen sections 
with fluorescent CGRP and visualizing with confocal microscopy. We found that in the 
neonates, CGRP density decreases in the WT with OVA treatment compared to WT PBS 
mice (Fig. 6.9). We also found that the NT4_1_ maintain low levels of CGRP axons despite 
OVA treatment (Fig. 6.9). This may mean that CGRP is released from the NEBs rather 
than the CGRP+ axons into the BALF to reduce AHR in the NT4_1_ neonates. 
Dakhama et al. (203) showed that RSV infection increases AHR due to an imbalance in 
sensory neuropeptide expression of increased substance P and decreased CGRP levels. 
They found that CGRP has a neuro-protective role in RSV infection. Since the NT4_1_ 
pups have greater levels of CGRP in their BALF, CGRP may protect against AHR and 
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Figure 6.8 Increase in CGRP levels in NT41- neonatal BALF via slot blot. 
CGRP levels measured in dilute BALF and quantified. CGRP levels are normalized to 
total protein by ponceau stain. 
136 
A PBS OVA B 
0.04 
1-
s £ 0.03 
"' c Q) 
0 
ll. 0.02 
0:: 
(!) 
u 0.01 
0 
'). WT NT4-t-
~ N= 2 3 3 4 
< 
Figure 6.9 CGRP axon density decreases with OVA treatment and absence of NT 4. 
A. Representative images of lung slices fluorescently stained with CGRP and imaged by 
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mucin production. For a complimentaty assay, we will need to assess substance P levels 
in the NT4_1_ lungs. 
6.3.5 Muscimol 
We wanted to rescue this phenotype by adding GABA to the NT4_1_ and see if the GABA 
was sufficient to rescue mucus production. But GABA has a shmt half-life and may not 
reach the airway if delivered intratracheally. Therefore, we delivered a GABA alpha 
agonist, Muscimol, intratracheally first to WT mice to see if muscimol alone was 
sufficient to produce mucin. Muscimol had been used in other mouse studies to alter the 
brain and other behavioral activities. We tried four doses of muscimol and a vehicle 
control. However, none ofthe mice treated with muscimol were positive for PAS staining 
(Fig. 6.10). We thought that maybe the airway epithelium needed to be activated by 
inflammation in order to produce mucin. But since the WT OVA neonate already 
produced a ton of mucin in the airways, we could not treat the WT neonate with both 
OVA and mucimol and look at the levels of mucin production. Therefore, we next 
delivered both OVA and intratracheal muscimol to NT4_1_ neonates. Again, at P21 the 
NT4_1_ treated with muscimol and OVA failed to produce mucin. GABA has several 
isoforms. Muscimol only affects GABA alpha. It is possible that this isoform is not 
effective in the lung. It is also possible that muscimol may not be working. We need to 
test the drug activity on a cell line to see if it active. And there are also other GABA 
agonists like baclofen that may rescue the phenotype in NT4_1_. 
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Figure 6.10 GABA agonist not sufficient to induce mucin production in WT 
neonates. 
PAS stain ofP21 WT lungs treated with varying doses ofmuscimol. Scale bar is 100 J..!M. 
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6.3.6 Clara Cells 
Next, we looked to see if there were differences in goblet cell transdifferentiation from 
Clara cells. We stained the lungs for CCI 0, a marker of Clara cells. In neonatal mice, we 
found that OVA treatment may visually decrease CC 10 expression in the lung epithelium 
compared to WT PBS controls (Fig. 6.11 ). This would be consistent with studies that 
show that allergen challenge reduces Clara cell markers and increase goblet cell markers. 
It also seems like the NT4_1_ lungs do not have a change in Clara cells with OVA 
treatment (Fig. 6.11 ). This would imply that the NT4_1_ have a defect in goblet cell 
transdifferentiation possibly through lack of GABA signaling. However, this assay only 
has n= 1 and will need to be repeated and quantified. We will also need to perform the 
complimentary assay to see if the number of goblet cells is altered by OVA treatment. 
We also looked to see if this phenotype was the same in adult NT4_1_ mice. Using a 
histological index to quantify mucin positive airways, we compared mucin levels of WT 
and NT4_1_ mice in persistent asthma and adult acute asthma. We found that mucin 
production persisted into adulthood for the WT mice and that the NT4_1_ adult mice were 
capable of mucin production with late allergen exposure (Fig. 6.12). This meant that the 
mucin phenotype was developmental and that the defect is somehow corrected as the 
lung matured. 
Regardless of OVA treatment, NT4-/- neonates produce lower levels ofmucin compared 
to WT. While preliminary, our data indicate that the defect is downstream of IL-13 , 
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PBS OVA 
Figure 6.11 NT41- maintain normal levels of CClO with OVA treatment. 
Lungs stained with CC10 and DAPI. Scale bar is 100 ~-tM . 
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possibly NEBs making less GAD enzyme resulting in less GABA production, reduced 
Clara cell transdifferentiation into goblet cells, and thus less mucin in the airways (Fig. 
6.13). 
6.4 Discussion 
There is no question that understanding the mechanism of mucin production is crucial to 
alleviate morbidity and mortality in patients with respiratory disease. Here, we show 
preliminary data that NT4 is implicated in childhood asthma not only by increasing AHR, 
but also by increasing mucin production. 
However, there are limitations to each of these assays in determining why the NT4_1_ 
neonates do not produce mucin. The most definitive approach would be to rescue the 
mucin phenotype. Recent studies show that GABA may play a role in mucin production. 
In our model, we can test this by adding GABA or a GABA agonist directly to the OVA-
treated NT4_1_ neonatal lungs and look for mucin production. Although it is possible that 
there are other factors produced by the NEBs that play a role in mucin production. It is 
also possible that GABA alone may not be sufficient to rescue the phenotype. 
While the rescue experiment is ofupmost importance, we also need to finish 
characterizing the NT 4-l- neonatal lungs. IL-13 signals through the Jak/Stat6 pathway to 
upregulate HIFlalpha (196). Increased HIFlalpha levels increase transcription of 
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Figure 6.13 Schematic of mucous production via the GABA pathway. 
In the WT and NT4_1_ airways, allergen exposure increase IL-13 signaling in Clara cells to 
upregulate GABA receptors. In the WT airways, NEBs secrete GABA, which cause 
Clara cells to transdifferentiate into goblet cells and produce mucus. In the NT4_1_ airways, 
the NEBs have lower levels of Gad enzyme so they produce less GABA and the Clara 
cells do not transdifferentiate into goblet cells. 
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MUC5AC. More studies will be needed to examine the levels of the IL-13 receptor, Jak, 
Stat6, and HIF1alpha in the NT4_1_ neonatal lung epithelium. 
It is currently unknown how GABA signals downstream. And while studies show that IL-
13 may upregulate the GABA receptor, SPDEF, and HIFlalpha in epithelial cells, there 
may be other unidentified key players. To address this, we will perform a microarray on 
lung epithelial cells in the WT and NT4_1_ neonatal lungs with or without OVA treatment. 
Another approach would be to better characterize the NT4_1_ adult lungs since the mucin 
phenotype appears to be a developmental defect. We will need to assay GAD levels, clara 
cell numbers, goblet cell numbers in the OVA-treated adult NT4_1_ mice compared to NT4-
I- adult mice that were given OVA as neonates. 
Together, these experiments will uncover the mechanism of a ve1y interesting phenotype 
with the hopes of identifying novel drug targets to reduce mucin production. 
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CHAPTER 7: Conclusion 
7.1 Overview 
Understanding the development of lung innervation is important because innervation 
regulates lung functions such as coughing, breathing, mucus secretion and clearance, 
blood flow, and inflammation (6,14,204,205). A growing body of evidence now shows 
that impaired lung innervation can lead to improper lung development, COPD, and 
asthma. Here, we show that extrinsic lung innervation is dependent on TrkB signaling 
through BDNF embryonically, and NT4 postnatally. We also show that early allergen 
exposure increases NT4/TrkB signaling to increase ASM innervation and thus, airway 
hyper-reactivity, which persists through adulthood. Ablation ofNT4 and pharmacological 
inhibition of TrkB signaling decreases AHR and mucin production without affecting 
inflammation in allergen-challenged neonatal mice. A solid understanding of the 
development of lung innervation, under normal and pathophysiologic conditions, will 
bolster these studies and provide new pathways to explore. 
7.2 Lung transplantation 
Animal experimentation with lung transplants began in the 1940s and 50s. The first lung 
transplant in the United States was by James Hardy at the University of Mississippi in 
1963. Since the nerve axons are severed during lung transplantation, it was possible to 
observe functions for lung innervation. 
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Studies have shown that lung transplantation denervates the lung and alters pulmonary 
function (206-209). The physiologic changes that occur after vagotomy include 
impairment of cough and mucocilimy clearance, loss ofHerin-Beruer reflex, 
development of nonspecific airway hyperresponsiveness, and altered ventilator response 
to hypercapnia (204,21 0-217). After reimplantation, bronchial arteries (218) regenerate 
quickly, but nerves regenerate slowly (207,219) or not at all (5,220). Some studies have 
been interpreted to indicate that the cough reflex is permanently impaired in lung 
transplant recipients. However, partial recovery of airway reflexes after surgical 
denervation has been reported in canines 3-6 months after lung transplant (206) and in 
rats more than 6 months after airway transection (221). 
Following transplantation, there is an initial loss in lung innervation followed by 
reestablishment with sensory nerves ( 49). Lung transplantation studies in humans (222) 
have also shown that airways are capable of undergoing structural reinnervation, but 
there is a 40% mortality rate related to pneumonia (223), suggesting that the initial loss of 
the cough reflex predisposed patients to infections and premature death. So while the 
newly transplanted lung is capable ofbreathing independent of neural regulation, lung 
innervation still plays an important role in health and wellbeing. 
7.3 Characterize nerve type differences 
We show that overall levels of innervation are increased with early allergen exposure by 
immunohistochemistry and western blot analysis. Unfortunately, we were unable to 
147 
thoroughly characterize the types of nerves that were increased with OVA treatment. We 
tried histology (Fig. 5.5), genetic models (Fig. 5.6), airway physiology (Fig. 5. 7), 
vagotomy (Fig. 5.8), and electrical field stimulation (Fig. 5.9). We will need to work 
harder to polish these assays since neural peptide imbalance may be an important part of 
asthma pathology (Dakhama 2004). We have shown that sensory axon density (CGRP+) 
are decreased with OVA treatment in the WT neonates (Fig. 6.9), and increased after a 
five-week recovery without further OVA challenge (Fig. 3.3 E, F). Also, the NT4_1_ 
neonates have an increase in CGRP in their BALF, which may be protecting against 
AHR and/or mucin production (Fig. 6.8). 
Once we understand which nerve subtypes are altered with OVA exposure, we will look 
downstream of the axons and figure out which neuropeptides, like Substance P and 
acetylcholine, are playing a role in early allergen exposure. 
7.4 NT4 synthesis 
We have shown defmitively by cell sort and in situ hybridization that TrkB is not 
expressed in immune cells, ASM, epithelium, or alveolar spaces (Fig. 4 .5 and 4. 7). Thus, 
it is highly likely that TrkB is solely expressed on the axons in the lung. We were unable 
to see TrkB mRNA in the axons because it is likely that TrkB is synthesized in the neuron 
bodies that exist outside of the lung. But the question still remains: which cells make 
NT4? 
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Many studies on neurotrophin signaling in the brain show that neurotrophins are target-
derived. Studies have shown that neurotrophins, like NGF, are made in the ASM. Studies 
have also shown that almost every type of cell in the lung is capable of making 
neurotrophins. However, these conclusions are questionable since they are drawn from 
qPCR assays with high cycle numbers. Careful analysis of each lung cell population 
resident and recruited will need to be performed in order to know with confidence, which 
cells synthesize and secrete neurotrophins. Our preliminary studies show that mast cells 
make NT4 in vitro (Fig. 5.2). Mast cells are localized in between the ASM and 
epithelium and are likely candidates for NT4 secretion. We also showed that genetic 
reduction of mast cells reduces lung innervation levels (Fig. 5.4) and possibly AHR (Fig. 
5.3). Thus, it is highly likely that mast cells play a role in the increase in innervation due 
to early allergen exposure by NT4 secretion. 
7.5 ASM phenotype-array 
It is known that there is crosstalk between the nerves and their target tissue. One of the 
most notable findings from this study is that increased innervation from early allergen 
exposure altered the ASM phenotype (Fig. 4.9). We measured the ASM contractility in 
lung slices and single cell isolation so there was no direct nerve input at the time of 
measurement. This means that the nerves can change the ASM phenotype over time. We 
will perform similar measurements to see how long this phenotype persists. We also want 
to understand what these changes are at a molecular level. To do this, we will perform a 
microarray on isolated ASM from WT and NT4_1_ neonates treated with or without OVA. 
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These fmdings will be impmiant in understanding the mechanism of ASM hyper-
reactivity. 
7.6 Asthma subtypes 
Asthma is not a single disease, but a conglomerate of diseases. There are many different 
types of asthma like allergic, occupational, childhood, adult-onset, acute, chronic, 
exercise-induced, cough-variant, non-allergic, and nocturnal. This may help explain why 
some patients do not respond to generically presclibed asthma therapies like broncho-
dilators and corticosteroids. 
Here, we show that child-onset allergic asthma has a different pathophysiology compared 
to adult acute allergic asthma. While there are similarities between all of these diseases, it 
is highly likely that each has a different mechanism. Thus, it is crucial for future asthma 
studies to treat each asthma subtype as a different disease in order to develop tailored 
dmg therapies and to better inform patient treatment options. 
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7.7 Summary 
Asthma is a major global health burden. Some say it is a small price to pay for reducing 
small pox and polio outbreaks. However, quality oflife can be improved if we better 
understand asthma at a molecular level. While asthma research has continued for 
decades, there are still new pathways to explore. Here, we show that NT4ffrkB signaling 
is heavily implicated in the pathogenesis of childhood asthma and its persistence into 
adulthood. Our study opens up this field for new signaling pathways and therapeutic 
targets. 
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